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ABSTRACT 
 
Obesity Management Using Diacylglycerol and Low Glycemic Index Starch in Dogs. 
(May 2008) 
Daisuke Nagaoka, B.V.Sc., Nihon Veterinary and Animal Science University; 
Ph.D., Nihon University 
Chair of Advisory Committee: Dr. John E. Bauer 
 
Obesity is the most common nutritional disorder in small animal medicine and is 
closely related to the mortality and morbidity of various diseases.  Decreasing the 
incidence of obesity is considered to be the most important way to maintain health, 
prevent disease, and contribute to longevity.  Diet therapy using low glycemic index 
starch (LGIS) and diacylglycerol (DAG) may thus be a reasonable obesity management 
tool without unnecessary food restriction, forced physical activity, and impairment of 
health.  Beagles were prepared for a weight loss study by inducing obesity using a high 
caloric/human snack food combination.  These obese dogs were then fed diets containing 
either LGIS/HGIS and DAG/TAG for a 10 wk weight loss period.  The LGIS groups lost 
more weight than the high glycemic index starch (HGIS) groups (2% vs 1% per wk) due 
to lower total diet digestibilities.  Even though the dogs had consumed similar amounts 
of the diets on a weight basis, the amounts of metabolizable energy (ME) ingested 
overall differed between the two starch types.  Diet effects were found for plasma 
triglyceride (TG) at both wk 1 and 8.  Post-prandial TG lowering was observed only 
 iv 
with a LGIS/DAG diet combination.  LGIS groups showed less decreased post-prandial 
non esterified fatty acid (NEFA) concentrations compared with HGIS groups at both wk 
1 and 8.  At both wk 1 and 8, plasma insulin was significantly lower in the LGIS groups 
although glucose concentrations were similar among all groups.  Plasma gastric 
inhibitory polypeptide (GIP) increased in all groups but tended to be lower in the LGIS 
groups.  Significant time effects were seen in glucagon-like peptide-1 (GLP-1) at both 
wk 1 and 8; however, diet effects were not observed.  Plasma adiponectin concentrations 
were significantly higher in the LGIS/DAG group vs. all other diet groups.  Significantly 
lower plasma leptin concentrations were found, especially in the LGIS/DAG group.  
Combinations of LGI starch and oils decreased uncoupling protein-2 (UCP2) mRNA 
gene expression in the small intestine compared with the combinations of HGI starch 
and oils.  These findings indicate that the LGIS/DAG combination beneficially supports 
more efficient and healthy weight loss in dogs along with improvement in biochemical 
and hormonal biomarkers.  This combination may be preferred for healthy canine weight 
loss and to help prevent obesity related diseases. 
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NOMENCLATURE 
 
BCS Body Condition Score 
BF Body Fat 
BW Body Weight  
DAG Diacylglycerol 
GIP Gastric Inhibitory Polypeptide 
GLP-1 Glucagon-like peptide-1 
HGIS High Glycemic Index Starch 
LGIS Low Glycemic Index Starch 
ME Metabolizable Energy 
NEFA Non Esterified Fatty Acid 
NFE Nitrogen-Free Extract 
TAG (TG) Triacylglyceride 
UCP Uncoupling Protein 
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CHAPTER I 
INTRODUCTION 
 
Obesity is a well-known, growing global problem in humans (Kopelman, 2000) 
and, as in humans, the incidence of obesity in the companion animal population is 
increasing.  Obesity is usually defined as an accumulation of excessive amount of adipose 
tissue in the body.  Cats and dogs are considered overweight when their body weight is 
more than 15% above their optimal body weight, and obese when their body weight 
exceeds 30% of optimal body weight (Burkholder and Toll, 2000).  It is estimated that 40 
to 50% of dogs and 20% of cats seen by veterinarians are overweight and that 25% of 
dogs and 5% of cats are obese (Bauer, 2005).  In the United States, it is estimated that 24 
to 30% of the pet population seen by veterinarians is overweight or obese (Remillard, 
2005).  Studies from various parts of the world have estimated the incidence of obesity in 
the dog population to be between 22 and 40% (McGreevy et al., 2005).  In view of these 
data, a moderate estimate is that 25% of dogs are obese. 
Obesity is the most common nutritional disorder in small animal medicine and it 
can be primary or secondary.  Secondary causes of obesity include hypothyroidism, 
hyperadrenocorticism, or insulinomas (Remillard, 2005).  However, the primary cause of 
obesity is simply defined as a disequilibrium between energy uptake and expenditure. 
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 Obesity is also closely related to the rate of occurrence of various diseases.  
German (2006) recently summarized numerous diseases reported to be associated with 
obesity in companion animals.  It included metabolic abnormalities, endocrinopathies, 
orthopedic disorders, cardiorespiratory disease, urogenital disorder, neoplasia, and 
functional alterations (German, 2006). 
 In view of the comprehensive nature of obesity related disorders, decreasing the 
incidence of obesity is considered to be a most important way to maintain health, prevent 
disease, and contribute to longevity. 
 In general, recommendations for obesity management are to decrease calorie intake 
and increase energy expenditure to promote weight loss (Laflamme, 2006).  Several 
exercise strategies in dogs have been suggested including lead walking, swimming, 
hydrotherapy, and treadmills (German, 2006).  However, like humans, dogs and cats are 
vulnerable to hunger stress and dietary restriction may increase such stress in the animal 
as well as their owners.  One recent focus in companion animal nutrition has been to alter 
macronutrient composition including protein, carbohydrates, or fat type and amounts and 
to study the impact such modifications have on animal obesity prevention and therapy 
(Butterwick and Hawthorne, 1998; Delzenne and Kok, 1999; Hill et al., 2006; Streiff et 
al., 2002).  In addition to increasing physical activities, dietary therapy can be a best 
solution for obesity management. 
Significance of Diacylglycerol Oil 
 Diet therapy using dietary diacylglycerol containing vegetable oils (DAG), 
especially 1,3-DAG, have been studied in recent years and may be a reasonable obesity 
management tool for humans (Maki et al., 2002).  DAG are naturally occurring 
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components of edible vegetable oils.  They have distinct characteristics from the 
triacylglycerols (TAG) that are typically found in such oils.  As such, DAG may produce 
beneficial effects separate from TAG on post-prandial lipemia, insulin response to 
feeding, and obesity prevention and therapy.  DAG oil is similar in taste, appearance, and 
fatty acid composition to other oils including rapeseed, soybean, and safflower oil 
(Takase et al., 2005).  In general, DAG appears to have two broad-based health benefits: 
Suppression of post-prandial serum triglyceride elevations and suppression of body fat 
accumulation (Yasukawa and Katsuragi, 2004).  A potential explanation for these 
benefits is that the metabolic characteristics of 1,3-DAG are less likely to become stored 
as body fat due to increased β-oxidation of their component fatty acid and then less 
efficient re-esterification in tissue cells. 
 TAG, a primary component of normal edible oil, is absorbed in the small intestine 
as a form of 2-monoacylglycerol (MAG), resynthesized to TAG, and incorporated into 
chylomicrons, which are released into the intestinal lymph and then enter the blood 
stream.  By pancreatic lipase, fatty acids from the sn-1 and sn-3 position of TAG are 
hydrolyzed, resulting in the breakdown of TAG into 1,2-(2,3-) DAG, which can be 
further hydrolyzed into sn-2 MAG and free fatty acid (FFA) (Lykidis et al., 1995).  In the 
intestinal epithelial cells, FFAs are bound to the sn-1 and sn-3 positions of 2-MAG via 
the 2-MAG pathway (Friedman and Nylund, 1980).  TAG have been shown to be 
resynthesized via the MAG pathway through two steps of enzyme action, the acylation of 
2-MAG and the subsequent acylation of 1,2-DAG (Kondo et al., 2003).  
Monoacylglycerol acyltransferase (MGAT) and diacylglycerol acyltransferase (DGAT) 
are the key enzymes for chylomicron TAG resynthesis.  The microsomal enzyme, 
  
4 
DGAT, is especially important in that it catalyzes the last step in the synthesis of TAG 
and has higher substrate specificity for 1,2-DAG compared with 1,3-DAG (Watanabe and 
Tokimitsu, 2004). 
 By contrast, 1,3-DAG is digested as 1-MAG and is poorly re-esterified to TAG.  It 
is believed that 1,3-DAG is not utilized extensively by DGAT as a substrate for 
chylomicron triacylglycerol synthesis because DGAT generally resynthesizes 
chylomicron triglycerides using 1,2-DAG as the substrate.  This factor may be one reason 
for the suppression of post-prandial triglyceride elevations (Kondo et al., 2003) seen with 
DAG enriched oils.  Therefore, including DAG as a part of a total diet may support 
decreased re-synthesis of TAG and delay its release as lymph chylomicrons (Yasukawa 
and Katsuragi, 2004). 
 Effects of DAG on energy metabolism have also been reported.  Dietary DAG 
intake increased mRNA expression and increased the activity of beta-oxidation-related 
enzymes in the small intestine and the liver (Murase et al., 2001; Murase et al., 2002).  
These authors also reported that the mRNA expression of uncoupling proteins increased 
in the liver and small intestine (Murase et al., 2001; Murase et al., 2002).  Energy 
expenditure enhancement (Kimura et al., 2003) and respiratory quotient decrement 
(Kimura et al., 2003; Kamphuis et al., 2003) were also noted when dietary DAG was 
ingested. 
 Although several beneficial effects of DAG in humans and rodents have been 
reported, only a few studies regarding DAG in dogs and cats have been reported to date 
(Umeda et al., 2006; Bauer et al., 2006).  Thus additional information is needed in order 
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to more fully evaluate DAG containing oils as a useful component of companion animal 
diets. 
 In the view of safety aspects, several reports exist concerning the long-term 
consumption of DAG in humans (Yasunaga et al., 2004), rodents (Soni et al., 2001; 
Kasamatsu et al., 2005), and dogs (Chengelis et al., 2006).  A chronic study of 
diacylglycerol oil in rats showed no compound-related effects on clinical signs, body 
weights, food consumption, cumulative survival rates, hematology, blood chemistry, 
urinalysis, organ weights, or on microscopic non-neoplastic changes (Soni et al., 2001).  
Even though epithelial mammary gland neoplasms were observed in the control groups, 
these changes were not considered biologically significant and the neoplastic findings 
were not dose related (Soni et al., 2001).  The authors revealed that no toxicologically 
significant or treatment-related effects of diacylglycerol oil consumption at levels of up to 
5.3% in the diet were seen during a two-year chronic rat study. 
 Studies in humans using double-blind clinically controlled experiments investigated 
the consumption of high-dose dietary diacylglycerol oil compared with triacylglycerol 
control oil (Yasunaga et al., 2004).  A 12 wk clinical study revealed that there was no 
significant difference in the occurrence of clinical signs and physical complaints related 
to test oil consumption.  Although some statistically significant effects were reported in 
hematological and serum chemistry parameters in both DAG and TAG groups, none of 
these reported changes were considered biologically significant.  The authors concluded 
that no significant or treatment-related adverse effects of DAG oil consumed at a dose of 
0.5 g/kg of BW/d as part of a normal diet were seen. 
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 Another safety study was conducted using rats, mice, and cultured Chinese hamster 
lung cells (Kasamatsu et al., 2005).  In their study, DAG oil, both before and after heating 
did not show any genotoxic effect.  They concluded that there are no safety concerns on 
the genotoxicity of DAG oil under the conditions of normal use. 
 Chronic dietary toxicity of DAG in beagles has also been studied (Chengelis et al., 
2006).  The results indicated that the clinical condition of the animals, body weights, 
body weight gains, food consumption, hematology, urinalysis parameters, and serum 
chemistry were not affected by DAG.  Electrocardiogram, histopathologic findings, and 
changes in organ weights were also unaffected by DAG diet compared with TAG control 
diet.  The authors concluded that DAG at dietary concentrations up to 9.5% for one year 
had no effect on normal canine growth and development compared with TAG.  From 
these safety awareness reports, several authors proved that long-term consumption of 
diacylglycerol oil as part of diet is safe and worth trying. 
Studies in mice and humans 
 Previous studies in obesity prone mice have shown that feeding a diet high in 
DAG compared to TAG resulted in significant decreases in body weight and lower feed 
efficiencies even though energy intakes were not different (Murase et al., 2001).  Because 
absorption rates of dietary DAG are not different from TAG (Taguchi et al., 2001; 
Taguchi et al., 2003), it is unlikely that a difference in energy intake or absorption caused 
the observed differences.  In addition, when DAG was fed, fat pad weights were less after 
5 months of feeding and less fat accumulation was found in all four anatomical areas 
examined; epididymal, mesenteric, retroperitoneal, and perirenal.  Other results of this 
study observed that structural differences between DAG and TAG markedly affected the 
serum lipid profiles.  Also, lower hyperinsulinemic responses and lower elevation of 
serum leptin concentrations were noted. 
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 Studies in humans using double-blind clinically controlled experiments 
investigated post-prandial lipemia in healthy men after the ingestion of test emulsions 
containing either DAG or TAG.  Serum TAG concentrations increased significantly 
relative to fasting in both groups.  However, when relative amounts of post-prandial 
hypertriglyceridemia were compared by calculating the areas under the serum TAG 
curves over a 6 h period, it was found that mean DAG values were significantly less then 
that of the TAG group.  Post-prandial concentrations of serum cholesterol, insulin, and 
glucose were unchanged in this study (Taguchi et al., 2000). 
Studies in dogs 
 Studies in dogs to date have included evaluation of DAG feeding in a group of 
privately owned obese dogs in their homes (personal Kao communication).  After a diet 
run-in period of 4 wk using a common diet, 11 dogs were fed a TAG enriched complete 
and balanced diet while 10 were fed the same diet supplemented with DAG for an 8 wk 
period (unpublished).  The test diet contained a total fat content of 15% as-fed.  At the 
end of an 8 wk period, it was found that the DAG group lost a significant amount of 
weight compared to TAG of approximately 0.5% of their starting body weight per week.  
The owners had been instructed to feed their dogs the same volume of food as usual, the 
same treats as usual, and exercise as usual.  Thus the weight loss appears to have been 
attributed to the DAG containing diet. 
 A second study was conducted using obese dogs (BCS > 4/5) in a kennel 
environment and employed TAG and DAG oil containing diets (Umeda et al., 2006).   
26 dogs were evenly divided and were fed either DAG or TAG diet, both at isocaloric 
amounts based on the amount of energy needed to maintain their overweight condition.  
Diet compositions incuding fatty acid profiles and digestibilities of the diets were the 
same with the only difference being oil type; ca. 38% DAG in the DAG diet and ca. 7% 
DAG in the TAG Diet.  Statistically significant reductions in body weight and body fat 
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mass was observed during a 6 wk dietary period which averaged approximately 0.5% of 
initial body weight lost per week.  There were no significant differences in digestibility 
and average calorie intake.  Serum TG and cholesterol levels were significantly decreased 
in the DAG group and increases in β-hydroxybutyrate were noted consistent with 
previous findings in dogs and other species. 
Significance of Low Glycemic Index Starch 
 Compared to studies with DAG, many investigation have been conducted using 
different types of glycemic index starches in humans, small, and large animals. 
 Starch is a primary energy source for omnivorous animals (Guilbot and Mercier, 
1985) and can be separated into four distinct groups such as absorbable, digestible, 
fermentable, and nonfermentable, depending on their degree of polymerization and 
digestibility (Nantel, 1999).  Starch is a nonstructural plant storage polysaccharide 
(Englyst, 1989) and is the main carbohydrate in cereal grains (Bach-Knudsen, 1997).  
Dietary starch is composed of amylose (linear glucose chain with α-1,4-glucosidic 
linkages) and amylopectin (branched glucose polymer containing both α-1,4- and α-1,6-
linkages). 
 Starch digestibility is affected not only by processing but also by plant species.  
High-amylose corn (low glycemic index, LGI) starch is a starch from amylomaize corn 
that has an amylose content higher than 50%.  High-amylose corn is grown exclusively 
for wet-milling.  Usually, high amylose corn starch is used in textiles, candies and 
adhesives (Thomison, 2004).  Waxy corn (high glycemic index, HGI) is a starch variant 
of normal corn and usually used by wet-corn millers to produce waxy cornstarch which is 
utilized by the food industry as a stabilizer/thickener and in the paper industry as an 
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adhesive.  Waxy corn contains 100% amylopectin whereas normal corn contains 75% 
amylopectin and 25% amylose (Thomison, 2004). 
 Nguyen et al. (1998) reported that postprandial hyperglycemia and insulin secretion 
depend on the ratio of amylose to amylopectin consumed.  These authors found a positive 
linear correlation between the starch content of foods and postprandial plasma glucose 
and insulin response curves, demonstrating that the amount of starch consumed from 
different complete diets is also a major determinant of the glycemic response of healthy 
adult beagles (Nguyen et al., 1998). 
 Studies in normal and diabetic Sprague-Dawley rats found that plasma triglycerides 
were not significantly affected by the type of starch (Kabir et al., 1998).  Also, adipose 
tissue and liver lipoprotein lipase (LPL) activities were not modified by the type of starch 
in the diet. In diabetic rats, a waxy cornstarch diet induced high basal plasma insulin 
levels.  A second study was conducted by the same authors.  To evaluate the role of 
insulin in this phenomenon, two genes regulated by insulin [GLUT4 and 
phosphpenolpyruvate carboxykinase (PEPCK)] were investigated.  The high glycemic 
index waxy cornstarch diet compared with the low glycemic index diet resulted in lower 
hepatic PEPCK mRNA in both normal and diabetic rats.  They concluded that high 
glycemic index starch diet is implicated in stimulating fatty acid synthase (FAS) activity 
and lipogenesis and might have undesirable long-term metabolic effects (Kabir et al., 
1998). 
 A similar study was conducted in humans investigating long-term consumption of 
high-amylose starch on insulin and glucose response in hyperinsulinemic subjects 
compared with normal controls.  Areas under the curves for the insulin response was 
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significantly lower in all subjects after high-amylose consumption.  Glucose responses in 
hyperinsulinemic subjects and control subjects were also similar and did not vary with 
the type of starch.  Fasting plasma triglyceride concentrations were significantly lower in 
subjects who consumed the high-amylose compared with the standard-starch diet 
throughout the study.  The authors concluded that chronic consumption of high-amylose 
foods (i.e. low glycemic index) normalized the insulin response of hyperinsulinemic 
subjects and showed a potential benefit for diabetic subjects (Behall and Howe, 1995). 
 It has been reported that high glycemic index starches increase body weight and can 
be a risk factor for diabetes (Pawlak et al., 2004).  Studies in several rodents fed different 
glycemic index starches in addition to other nutritional components indicated that rats 
given high glycemic index food had more body fat and less lean body mass than those 
given low glycemic index food.  Even though both diet groups consumed the same 
amount of food and gained the same amount of body weight for 7 wk, the HGI animals 
had developed hyperinsulinemia.  The HGI group also had greater increases, over time, in 
the areas under the curve for blood glucose and plasma insulin, lower plasma adiponectin 
concentrations, and higher plasma triglyceride concentrations compared with LGI groups.  
Also, mice on the HGI diet had almost twice the body fat of those on the LGI diet after 9 
wk. The authors concluded that consumption of a HGI diet per se adversely affects body 
composition and risk factors for diabetes and cardiovascular disease in animal models 
(Pawlak et al., 2004).  In addition, several reports are available that indicated a HGI diet 
has been linked to increased risk of type 2 diabetes independent of body weight in 
humans (Salmeron et al., 1997a; Salmeron et al., 1997b; Ludwig, 2002). 
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Preliminary Study 
 Preliminary studies using non-obese beagles were performed in our laboratory and 
study results have provided some useful information on the combined effects of DAG 
and starch type.  The protocol for this study was approved by the Texas A&M University 
Laboratory Animal Care Committee (AUP # 2003-177: Evaluation of dietary 
diacylglycerol oil on post-prandial response).  All dogs were housed at the Laboratory 
Animal Research and Resources (LARR) facility, Texas A&M University and 
individually maintained in kennels according to the American Physiological Society 
Guidelines for Animal Research and according to guidelines set forth by Texas A&M 
University Care and Use Committee.  Prior to entering the study, all dogs had complete 
blood counts, serum biochemistry profiles tests performed to assure normal clinical 
status.  All dogs used in the study appeared to be clinically and physiologically normal.  
The study was conducted to evaluate the post-prandial response of a single DAG/starch 
containing meal in twelve adult female beagles.  Each meal contained 60 g of cooked 
boneless chicken breast (locally purchased) mixed with 20 g of vegetable oil high in 
either DAG or TAG (Kao Corporation, Tokyo, Japan).  Either 25 g of gelatinized waxy-
corn starch (high glycemic index starch, HGIS) or high amylose corn starch (low 
glycemic index starch, LGIS) were also included (Nihon Shokuhin Kako Co., Ltd., 
Tokyo, Japan).  Four meals were evaluated and their nutrient composition (percent 
metabolizable energy, ME, basis) was 16.5% ME protein, 25.3% ME NFE, and 58.3% 
ME fat.  The post-prandial response of dogs fed each of the diets was evaluated using a 
crossover design with 2 wk washout periods between meals.  Blood samples were 
collected after withholding food overnight (time 0).  The meals were then fed and blood 
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samples were collected at times 0.5, 1, 2, 3, 4 and 6 h via jugular catheter.  All individual 
dogs received each of the four treatment meals in random order.  Plasma triglyceride 
(TG), non-esterified fatty acid (NEFA), glucose, and insulin were determined.  
Significant differences were found for both the peak and extent of hypertriglyceridemia 
when the DAG diets were consumed.  When LGI carbohydorate was included, a peak 
serum non-esterified fatty acid response was seen after 2 to 3 h.  HGIS/TAG resulted in a 
more drastic decrease of NEFA early on (30 min).  Plasma NEFA also varied more 
widely in both TAG groups compared to DAG.  Post-prandial glucose and insulin 
concentrations demonstrated greater peak elevations with HGIS.  The area under the 
curves of the serum glucose and insulin responses were also greater with HGIS meals. 
 Based on the preliminary data, the LGIS/DAG combination lowered post-prandial 
TG, insulin, yielded a more consistent postprandial glucose response, and showed an 
increased NEFA response compared to the other diet combinations.  The physiological 
significance of these findings remain unknown and additional studies are warranted, but 
these results are consistent with earlier studies. 
 In summary, diet therapy using DAG may be effective for the management of 
obesity, help prevent obesity related disease, and improve quality of life and longevity.  
In this sense, it is necessary and fruitful to accomplish additional functional 
investigations to further extend studies of LGIS/DAG combination and its effects on 
carbohydrate and lipid metabolism during weight loss. 
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Objectives and Hypothesis 
The overall objective of this dissertation is to further evaluate the effect of the 
combination of dietary diacylglycerol and low glycemic index carbohydrate with respect 
to its potential to support healthy weight loss in obese dogs.  Effects of triacylglycerol 
and high glycemic index carbohydrate were also be evaluated for comparative purposes.  
We hypothesized that the combination of DAG and LGI carbohydrate will support more 
efficient and healthy weight loss in beagles along with the improvement of selected lipid 
and adipose hormone biomarkers.  The effect of these fat and carbohydrate types during 
canine weight loss on several biochemical (glucose, non-esterified fatty acids, plasma 
triacylglycerol) and hormonal parameters (insulin, gastric inhibitory polypeptide, 
glucagons-like peptide-1, adiponectin, leptin) associated with lipid and energy 
metabolism were thus studied.  In addition, uncoupling protein-2 gene expression of 
small animal intestinal biopsy samples was also determined. 
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CHAPTER II 
INDUCTION AND RE-INDUCTION OF OBESITY 
 
Introduction 
 Treatment of companion animal obesity is a common nutritional problem in 
veterinary practice.  Most treatment regimens include reduced calorie intake and 
increased activity, but these are fraught with frustration.  A better understanding of 
obesity management in the pet population may come from modeling how obesity is 
initially induced under more controlled conditions in a colony setting.  Knowledge of key 
features such as the number of calories, length of time, and food types leading to obesity 
may provide animal owners with better advice regarding nutrition interventions.  In order 
to study the weight loss effect of LGIS and DAG in dogs, the animals were initially fed a 
high calorie diet in order to induce similar degrees of obesity.  Commercially available 
dog foods in combination with human food to mimic at home snacking and diet 
supplementation were used for this purpose.  In doing so, it was possible to follow the 
time course of obesity induction and better understand the occurrence of weight gain in 
these dogs. 
Materials and Methods 
Animals 
 The protocol for this study was approved by the Texas A&M University Laboratory 
Animal Care Committee (AUP # 2004-201, Evaluation of dietary DAG oil in obesity 
management).  All dogs were housed at the Laboratory Animal Research and Resources 
(LARR) facility, Texas A&M University and individually maintained in kennels 
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according to the American Physiological Society Guidelines for Animal Research and 
according to guidelines set forth by Texas A&M University Care and Use Committee.  
Prior to entering the study, all dogs had complete blood counts and serum biochemistry 
profiles tests performed to assure normal clinical status.  All dogs used in the study 
appeared to be clinically and physiologically normal. 
 Normal to modestly overweight (body condition scores (BCS) from 6 to 8 out of 9), 
sexually intact adult female beagles, ages 2 to 6 yr old, were used in the study (n = 9).  
All dogs were individually housed in approved sized kennels with 12 h light cycles, 
allowed free access to water and exercise, and fed free choice during the study.   
Diets and feeding 
 All dogs were initially fed twice their daily calculated number of calories 
(2×125(BWkg)0.75) using a combination of dry extruded commercial pet food (Hill’s 
Science diet, Adult Original, Hill’s Pet Nutrition, Inc., Topeka, KS) and locally 
purchased 50/50 (w/w) blend of canola and soy bean oils (40 g/d).  After 3 wk, all dogs 
were fed this mixture along with 5 Pecan shortbread cookies (Keebler, Inc, Elmhurst, IL) 
for the next 16 wk (obesity induction period: week 4 to 19).  All dogs were then subjected 
to a weight loss regimen using the treatment diets for the next 20 wk (wk 20 to 39) (See 
Chapter III).  After the weight loss period, obesity was re-induced (obesity re-induction 
period: week 40 to 56) according to the following regimen: double ration, 40 mL 
vegetable oil, plus 4 cookies (wk 40 to 49): double ration, 40 mL vegetable oil, plus 2 
cookies (wk 49 to 52), 40 mL vegetable oil, plus 1 cookie (wk 52 to 56).  During these 
time periods, kcal consumption, body weight, percent body fat calculated using 
bioelectrical impedance and BCS were monitored by same person. 
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Statistical analyses 
 Data are expressed as means ± SEM.  Statistical analyses of all data were 
performed using repeated measures ANOVA, to test for main effects of time and diet as 
well as the interaction of time with diet, and significance was set at P < 0.05.  Tukey test 
was used as a post-hoc test for multiple comparisons for main effects of diet, time, and 
diet x time interactions, at a level of significance of P < 0.05.  All data were found to 
follow a Gaussian distribution at P < 0.05 using the Kolmogorov-Smirnov (KS) test.  All 
statistical tests were performed using GraphPad Prism version 4.00 for Macintosh 
(GraphPad Software, San Diego, CA, www.graphpad.com). 
Results 
 No effort was made to quantify the amount of exercise of each animal and some 
variability was observed.  Only the amount of total calories offered daily was changed 
over time based on each animal’s starting body weight (10.4 to 14.3 kg range, 12.0 kg 
median). 
 Kcal consumed, body weight, and body condition scores during the initial obesity 
induction period are shown in Figure 1A.  A summary of body weights, BCS, percent 
body fat, and rate of weight gain is presented in Table 1.  After the first 3 wk, BCS had 
decreased somewhat and body weights were not significantly different.  The mean daily 
calorie intake averaged 1228 ± 48 kcal with ca. 2020 kcal/d offered (60% of total kcal 
offered).  Consumption was approximately 50% over calculated maintenance needs 
although 2.5 times more calories than maintenance calories were offered.  Thus some 
self-regulation of intake was observed during this initial 3 wk period. 
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Figure 1.  BW, BCS, and kcal/day consumption in obesity induction period. (A) Changes 
in body weight and BCS during induction period. (B) Changes in kcal/day 
consumption during induction period.  Values are mean ± SEM.  Letters not in 
common for a time point denote significant differences among diets by repeated 
measures ANOVA, P < 0.05. 
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Table 1. Summary of BW, BCS and percent body fat values during obesity induction/re-
induction periods. 
 
  Induction  Re-induction 
Body weight (kg)     
Start  12.17 ± 0.13  12.06 ± 0.33 
End  14.63 ± 0.14*  14.82 ± 0.22* 
BCS     
Start  7.44 ± 0.06  7.00 ± 0.13 
End  8.11 ± 0.10*  8.11 ± 0.07* 
% body fat     
Start  32.10 ± 0.66  34.10 ± 1.35 
End  40.20 ± 0.75*  41.00 ± 0.98** 
     
Rate of gain (kg/wk)  0.205 ± 0.012  0.251 ± 0.006*** 
     
Number of weeks to gain BCS = 8   15   10 
 
Percent body fat were determined by bioelectrical impedance. 
 
* Significant difference from start, P < 0.05 
** Significant difference from start, P = 0.07 
*** Significant difference from induction, P < 0.05 (n=8)
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 After the cookies were added (weeks 4 to 15), mean daily calorie consumption 
was increased to 1820 ± 137 kcal with ca. 2470 kcal being offered (74% of total kcal 
offered) (Figure 1B).  At wk 9, mean body weights were statistically significantly 
increased from those measured during wk 1 to 8. They continued to increase until wk 15 
after which a plateau was reached.  Similarly, BCS were significantly increased 
beginning at wk 9 and thereafter reaching a plateau at wk 14, P < 0.05.  Adding the 
human snack food (cookies) appeared to stimulate palatability of the entire ration overall. 
 During weeks 16 to 19, the average daily calorie consumption decreased to 1410 
± 70 kcal (ca. 25% of the amount consumed during week 4 to 15) even though the kcal 
offered remained constant (ca. 2470 kcal) (Figure 1B).  At this stage, the animals had 
reached an obese set-point (steady state) whereby they were able to maintain their obese 
body weights at a lower total caloric intake than that needed to achieve their obese state. 
 In the obesity re-induction period (week 40 to 56), increased rate of weight gain, 
BCS, and food efficiency became more prominent compared with the obesity induction 
period.  At wk 42, mean body weights were statistically significantly increased from 
those measured during the initial 2 wk period (week 40 to 41) (Figure 2A). They 
continued to increase until wk 50 after which a plateau was reached.  BCS were 
significantly increased beginning at wk 41 and thereafter reaching a plateau at wk 49 
(Figure 2A).  During the entire obesity re-induction period, mean daily calorie 
consumption was 1022.36 ± 60.62 (mean ± SEM) kcal and was not statistically 
significant different over all (Figure 2B). 
 Statistically significant food efficiency differences between induction and re-
induction periods were seen (Figure 3A and 3B). 
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Figure 2.  BW, BCS, and kcal/day consumption in obesity re-induction period. (A) 
Changes in body weight and BCS during re-induction period. (B) Changes in 
kcal/day consumption during re-induction period.  Values are mean ± SEM.  Letters 
not in common for a time point denote significant differences among diets by 
repeated measures ANOVA, P < 0.05. 
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Figure 3.  Food efficiency (BW / kcal consumed) between induction and re-induction 
periods.  (A) Total mean food efficiency.  Values are mean ± SEM.  Letters not in 
common for a body weight/kcal consumption denote significant differences 
between period by two-tailed paired t-test, P < 0.05.  (B) Comparison of food 
efficiency in each weak.  Values are mean ± SEM.  Asterisk denote significant 
differences between periods by repeated measures ANOVA, P < 0.05.  Week values 
in parentheses denote the actual week of the entire study period. 
  
22 
Food efficiencies (body weight/kcal consumption) were: induction period, 0.009 ± 
0.0002; and re-induction period, 0.014 ± 0.0009 (mean ± SEM). 
 With respect to re-induction of obesity using the same foods, it should be noted 
that fewer kcal/day were needed to re-induce the same degree of obesity in the dogs and 
that less time (15 week vs. 10 week, Table 1) was needed to do so.  Rate of weight regain 
was significantly shorter than for the initial obesity induction (Table 1). 
Discussion 
  This study investigated the relationship between rate of weight gain and calorie 
intake in a group of adult female beagle dogs.  It has also documented the relationship 
between calorie consumption and regain of body weight after weight loss. 
 Dieting is often accompanied with repeated bouts of weight loss and regain, a 
phenomenon called weight cycling, also known as yo-yo dieting (Blackburn et al., 1989; 
Brownell, 1989; Brownell and Rodin, 1994).  Several authors have suggested that weight 
cycling is a process of clinical importance because increased risks of morbidity and 
mortality may be associated with fluctuations in body weight (Ernsberger et al., 1996; 
Jeffery 1996).  Effects of weight cycling in humans (Goldbeter, 2006) and obesity 
induction/re-induction animal models (Brownell et al., 1986; Contreras and Williams, 
1989; Jandacek et al., 2004) have been reported.  Brownell et al. (1986) reported that the 
weight cycled animals showed significant increases in food efficiency (weight gain/kcal 
food intake) during the second restriction and re-feeding periods compared to the first 
periods.  Weight loss occurred at half the rate and regain at three times the rate in the 
second cycle.  Weight cycled animals had a four-fold increase in food efficiency 
compared to obese animals of the same weight who had not cycled at the end of the 
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study.  The authors concluded that frequent dieting may make subsequent weight loss 
more difficult. 
 Studies in Sprague-Dawley rats also revealed that three cycles of weight loss and 
weight regain resulted in the consumption of increased dietary fat, and increased food 
efficiency compared with control groups even though their body weights were similar 
(Contreras and Williams, 1989).  Goldbetter (2006) suggested in his study that 
maintaining weight under a critical value should prevent weight cycling and allow body 
weight to stabilize. 
 According to the review article of Prentice et al., the authors concluded that weight 
cycling suppresses the growth rate of young animals and increases metabolic efficiency.  
It may also increase the rate of weight gain in the immediate post-restriction phases after 
repeated cycles (Prentice et al., 1992). 
 In this study, we also observed a significant increase of food efficiency in the 
obesity re-induction period compared with the obesity induction period.  It was found that 
once body weight of obese dogs had been reduced, fewer calories were needed to regain 
the obese steady state.  For that matter, the rate of weight gain was greater and at an even 
lower calorie intake during re-induction of obesity.  These results demonstrate the effects 
of yo-yo dieting on energy metabolism resulting in the rapid regain of body weight after 
successful weight loss.  Our results also suggest that metabolic “down-regulation” of 
energy needs with weight loss regimens continues after target weights have been 
achieved. 
 Finally, it should be noted that in this canine model of obesity, human snack foods 
appeared to stimulate appetite and increase the overall net calorie consumption of the 
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total ration.  They provide a calorie dense dietary supplement leading to the rapid 
induction of an obese steady state that requires fewer calories to maintain.  This 
information may help pet owners better understand the need to limit table scraps and 
human-type food snacks in dogs prone to overweight and obesity. 
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CHAPTER III 
LIPID METABOLIC AND HORMONAL ALTERATIONS WITH 
DIACYLGLYCEROL AND LOW GLYCEMIC INDEX STARCH DURING 
CANINE WEIGHT LOSS 
 
Introduction 
 Obesity is usually defined as an accumulation of excessive amounts of adipose 
tissue in the body.  Cats and dogs are considered overweight when their body weights are 
more than 15% above their optimal body weight, and obese when their body weight 
exceed 30% of optimal body weight (Burkholder and Toll, 2000).  Obesity, the most 
common nutritional disorder in small animal medicine, is associated with several 
metabolic diseases.  Therefore, decreasing the incidence of obesity is important for 
animal health.  Diets to help prevent or manage canine obesity should ideally reduce 
calorie intake while providing satiety.  Increased diet fiber has been studied in canine 
weight loss diet formulas, but the effects of digestible carbohydrate types including high 
vs. low glycemic index varieties have not.  Also, reduced fat formulas have been 
employed but less is known about the type and form of dietary fats used.  Most vegetable 
oils contain predominately triacylglycerols with small amounts of diacylglycerols.  A 
newly available vegetable oil has been developed containing 80 percent DAG and it has 
been studied in rodents and humans (Taguchi et al., 2000; Taguchi et al., 2001). 
 As mentioned in the preliminary study, we indicated that some lipolytic activities, 
lipids, and carbohydrate metabolism are altered in dogs fed a DAG and low-glycemic 
index starch combination (Bauer et al., 2006).  To further extend this preliminary study, 
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and to investigate longer term weight loss, the effects of a diacylglycerol/low glycemic 
index starch combination diet was used to further evaluate several plasma parameters 
associated with obesity and weight loss. 
 Among the hormonal changes seen in obese vs. normal weight populations, 
alterations of insulin, adiponectin, and leptin have been reported and may also include 
changes in gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) 
(Carlson et al., 2007; Huypens 2007; McClean et al., 2007). 
 Glucagon-like peptide-1 is primarily secreted from the distal small intestine and 
large intestine in response to intraluminal glucose and lipid.  GLP-1 not only inhibits 
gastric acid secretion, but is also involved in the regulation of insulin secretion and 
glycemic control (Rehfeld, 1998; Furness et al., 1999).  Gastric inhibitory polypeptide, 
also known as glucose-dependent insulinotropic polypeptide, is secreted primarily from 
the duodenum in response to intraduodenal glucose, fatty acids, and amino acids.  Major 
roles of GIP are inhibition of gastric acid secretion and stimulation of intestinal fluid 
secretion.  Furthermore, GIP stimulates pancreatic insulin release during hyperglycemia 
(Meier et al., 2002) and dose dependently stimulates the release of GLP-1 (Damholt et 
al., 1998).  Binding of GIP and GLP-1 to its common receptor causes activation, via a 
stimulatory G-protein, of adenylate cyclase resulting in the formation of cAMP (Holst, 
2004).  Hormone sensitive lipase (HSL) is therefore released and lipolysis may occur.  
Thus, these incretin hormones are related to not only carbohydrate metabolism, but also 
affect lipid metabolism and may be involved in body weight regulation. 
 Adiponectin is an adipocytokine synthesized and secreted exclusively by adipose 
tissue and found at an almost three-order higher concentration in blood than other 
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adipocytokines (Chandran et al., 2003).  It is also widely recognized that adiponectin is 
one of the key factors of pathogenesis of atherosclerosis, insulin resistance, and diabetes 
mellitus (Ouchi et al., 2001; Kondo et al., 2002).  The synthesis and secretion of 
adiponectin is increased by activation of the nuclear receptor, PPARγ, and reduced by 
caloric excess, presumably associated with leptin deficiency or resistance (Saltiel, 2001).  
Adiponectin also activates PPARα.  Once released, adiponectin increases fatty acid 
transport directly, stimulates its oxidation and dissipation in skeltal muscle, and reduces 
the levels of intramyocellular lipids, thus improving insulin signaling (Saltiel, 2001).  
Therefore, administration of adiponectin results in improved insulin sensitivity and 
glucose tolerance, and modifies hyperglycemia related to obesity.  Under the obese 
condition, plasma adiponectin concentrations become lower, whereas plasma leptin 
concentrations become higher. 
 Leptin is a protein synthesized and secreted primarily by adipose tissue (Zhang et 
al., 1994).  In humans and rodents, blood leptin concentration is known to positively 
correlate with body fat content and is higher in obesity (Maffei et al., 1995; Tasaka et al., 
1997).  Leptin, secreted from adipocytes via the blood stream, binds to the leptin receptor 
in the hypothalamus.  It is considered that leptin regulates food intake to decrease 
appetite in a satiety center.  Meanwhile, it also activates the sympathetic nervous system 
and increases energy expenditure (Friedman and Halaas, 1998).  Under the obese 
condition, plasma leptin concentrations are increased (Maffei et al., 1995).  Furthermore, 
canine leptin is confirmed to have high homology with other animal species (Ishioka et 
al., 2002a).  Based on these data, it is believed that measuring plasma leptin can be a 
reliable marker to estimate the degree of obesity in dogs. 
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Materials and Methods 
Animals 
 The protocol for this study was approved by the Texas A&M University Laboratory 
Animal Care Committee (AUP # 2004-201: Evaluation of dietary DAG oil in obesity 
management).  All dogs were housed at the Laboratory Animal Research and Resources 
(LARR) facility, Texas A&M University and individually maintained in kennels 
according to the American Physiological Society Guidelines for Animal Research and 
according to guidelines set forth by Texas A&M University Care and Use Committee.  
Prior to entering the study, all dogs had complete blood counts and serum biochemistry 
profiles tests performed to assure normal clinical status.  All dogs used in the study 
appeared to be clinically and physiologically normal. 
 Twelve obese, sexually intact adult female beagles, ages 2 to 6 yr old, with body 
condition scores of  8 to 9 on a 9 point scale, where 5 is ideal, were used in the study.  All 
dogs were individually housed in approved sized kennels with 12 h light cycles, allowed 
free access to water and exercise, and fed free choice during the study. 
Diets and feeding 
 To conduct this study, three experimental stages were used; obesity induction 
period (week -8 to -5), acclimation period (week -4 to -1), and experimental period (week 
1 to 10).  Several different diets were used during these stages; preconditioning diet 
(week -8 to -5), acclimation diet (week -4 to -1), and four treatment diets  (week 1 to 10) 
suitable for each experimental stage.  Each stage and its corresponding diet information is 
fully described in Appendix A-I and are briefly described below. 
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 During obesity induction (week -8 to -5), all dogs were fed a combination of dry 
extruded commercial pet food (Hill’s Science Diet, Adult Original. Hill’s Pet Nutrition, 
Inc., Topeka, KS), a mixture (50:50 w/w) of canola and soy bean oil (40 g/d) plus 4 to 5 
pecan shortbread cookies (Keebler, Inc, Elmhurst, IL) as a preconditioning diet until 
body condition scores of > 8/9 were attained for all dogs.  During this time, calorie 
intake, body weight, and BCS were monitored weekly by same person to estimate the 
amount of energy needed to maintain their overweight condition.  After this 
preconditioning period, the dogs were randomly divided into one of four dietary groups 
(n = 3 per diet group).  Percent body fat content was determined using bioelectrical 
impedance as well as deuterium labeled water dilution techniques to determine a baseline 
estimate (Okawa et al., 2007).  The dogs were assigned to the diet groups to minimize 
bias with respect to age, BCS, and body fat content. 
 In the acclimation period (week -4 to -1), all dogs were fed a combination of a 
50/50 (w/w) blend of canola and soybean triacylglycerol oils, a 50/50 (w/w) mixture of 
the HGIS and LGIS starches, and sufficient amounts of water to maintain their obese 
condition and to accustom them to being fed the treatment diets with the same gruel-like 
texture.  This complete and balanced diet was formulated for canine maintenance.  The 
fatty acid profile of the acclimation diet can be found in Appendix A-II. 
 During the experimental period (week 1 to week 10), beginning at the end of week 
-1 (i.e. day 0), one dog from each group was fed its respective treatment diet using a 
Monday/Wednesday/Friday sequence until all dogs had begun their respective feeding 
periods (week 1).  As noted above, four diets were evaluated: the diets were combinations 
of: LGIS/DAG; LGIS/TAG; HGIS/DAG; and HGIS/TAG.  Ingredients used included 
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chicken by-product meal (Tyson Foods, Inc., Oklahoma City, OK); either high amylose 
corn (LGI) or waxy corn (HGI) starches that had been gelatinized (Nihon Shokuhin Kako 
Co., Ltd., Tokyo, Japan), either TAG or DAG enriched dietary oil (Kao Corporation, 
Tokyo, Japan), and appropriate mineral and vitamin pre-mixes suitable for canine 
maintenance (Akey, Lewisburg, OH) (Tables 2 and 3).  Additional details and nutrient 
composition of the treatment diets are also shown in Appendix A-III.  On a percent 
metabolizable energy basis, the diets contained approximately: 25% protein, 38% fat and 
36% nitrogen-free extract (NFE) (Table 3).  The diets were calculated using modified 
Atwater values to be isocaloric at approximately 4200 kcal/kg (Table 2). 
 On wk 1 and 8 of the feeding period, prior to collecting post-prandial blood 
samples, dogs were fed a post-prandial meal which was similar to the treatment diets 
except that boiled chicken breast meat was substituted for the chicken by-product meal 
yielding better palatability to assure rapid consumption.  The fatty acid profile of the 
boiled chicken can be found in Appendix A-IV.  The contents of this post-prandial meal 
were 80 g cooked chicken breast meat, 8 g oil (TAG or DAG) and 25 g starch (HGIS or 
LGIS).  Additional details and nutrient composition of the post-prandial diets are shown 
in Appendix A-V.  Food was withheld from the dogs overnight prior to time 0 blood 
sample collection and the post-prandial meal. 
 During week 3, a digestibility trial was conducted in which all feces from each dog 
was collected and frozen (-80°C) for 5 consecutive days, then pooled, for digestibility 
estimates via proximate analyses performed using a commercial laboratory (Midwest 
Laboratories, Inc., Omaha, Nebraska). 
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Table 2.  Compositions of treatment diets. 
 
 Diet 
Nutrient (g/kg) LGIS/DAG LGIS/TAG HGIS/DAG HGIS/TAG 
Chicken by-product meal 430 430 430 430 
DAG 135 - 135 - 
TAG - 135 - 135 
High amylose corn (LGI) starch 430 430 - - 
Waxy corn (HGI) starch - - 430 430 
Vitamins/mineral pre-mix* 5 5 5 5 
Water 1730 1730 2595 2595 
ME (kcal/kg)** 4300 4200 4900 4800 
 
*Copper (Cu): 4000 ppm, Iodine (I): 560 ppm, Iron (Fe): 2.40%, Manganese (Mn): 2000 
ppm, Selenium (Se): 120 ppm, Zinc (Zn): 4.32%, Vitamin A: 218 mg/kg (1600000 
IU/lb), Vitamin D3: 2.95 mg/kg (260000 IU/lb), Vitamin E: 5455 (5443) mg/kg (12000 
IU/lb), Vitamin B12: 1.82 mg/kg (4 mg/lb), Riboflavin: 272.7 mg/kg (600 mg/lb), d-
Pantothenic acid: 1364 mg/kg (3000 mg/lb), Thiamine: 75 mg/kg (165 mg/lb), Niacin: 
3182 mg/kg (7000 mg/lb), Vitamin B6: 90.9 mg/kg (200 mg/lb), Folic acid: 143.6 mg/kg 
(316 mg/lb), Choline chloride: 41227 mg/kg (90700 mg/lb), Choline: 35811 mg/kg 
(78784 mg/lb), d-Biotin: 4.5 mg/kg (10 mg/lb). *ppm = µg/g (mg/kg), vitamin A: 1 IU = 
0.3 µg, vitamin D3: 40 IU = 1 µg, vitamin E: 1 IU = 1 mg. 
 
**ME were determined from digestibility data. 
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Table 3.  Dry matter compositions of treatment diets. 
 Diet 
Diet (g/kg)* LGIS/DAG LGIS/TAG HGIS/DAG HGIS/TAG 
Protein 299.5 299.5 299.5 299.5 
Fat 197 197 197 197 
Carbohydrate 430 430 430 430 
Vitamins/Minerals 5 5 5 5 
Ash 4.71 4.71 4.71 4.71 
Water 1751.4 1751.4 2616.4 2616.4 
 
*ME were calculated from digestibility data using modified Atwater values.  24.8% ME 
protein, 39.6% ME fat, and 35.6% ME NFE. 
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 After the 10 wk weight loss regimen was completed (Period I), all dogs were again 
fed the preconditioning diet (re-induction of obesity).  After 16 wk similar degrees of 
obesity were re-induced and all dogs were again assigned to a treatment diet exactly 
opposite to the one they had been fed during Period I of the study and the study design 
repeated (Period II).  In this way, an n = 6 sample size was obtained for each diet studied.  
Start dates for each experimental stage were staggered to make the acquisition of samples 
manageable. 
Post-prandial blood samples 
 On weeks 1 and 8 of the feeding period, jugular catheters were placed in order to 
conduct post-prandial blood collection.  Food was withheld from the dogs overnight prior 
to each blood sample collection and a time 0 sample was collected.  Blood samples were 
then collected post-prandially at the following intervals: 15, 30, 60, 120, and 180 min.  
Samples were placed into EDTA-containing tubes for plasma separation by low speed 
centrifugation (2500 rpm at 4°C for 20 min).  A protease inhibitor was added to all blood 
samples to prevent proteolysis of small peptide hormones prior to centrifugation.  0.6 
TIU/mL of blood of aprotinin (Sigma-Aldrich Co., St. Louis, MO) was added for insulin 
analysis.  For GIP and GLP-1 analyses, 10 µL of dipeptidyl peptidase IV inhibitor (DPP-
IV inhibitor: Linco Research, St. Charles, MO) was added per mL of blood because DPP 
IV is a primary inactivating enzyme of both GIP and GLP-1 (Kieffer et al., 1995).  All 
plasma samples were stored frozen at -80°C until the time of analysis. 
Blood samples for adiponectin and leptin analysis 
On weeks 1, 4, 8 and 9 of the feeding period, fasting blood samples were 
collected for adiponectin and leptin analyses.  Food was withheld from the dogs 
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overnight prior to each blood sample collection.  Samples were placed into EDTA-
containing tubes for plasma separation by low speed centrifugation (2500 rpm at 4°C for 
20 min).  A protease inhibitor, 0.6 TIU/mL of blood of aprotinin (Sigma-Aldrich Co., St. 
Louis, MO) was added to all blood samples to prevent proteolysis of small peptide 
hormones prior to centrifugation.  All plasma samples were stored frozen at -80°C until 
the time of analysis. 
Analyses 
 Blood samples were analyzed for the following biochemical and hormonal 
parameters by enzymatic, or enzyme linked assays: Plasma triglyceride, non-esterified 
fatty acids, insulin, gastric inhibitory polypeptide, glucagon-like peptide-1, adiponectin, 
and leptin.  Post-prandial plasma samples were analyzed for glucose, TG, and NEFA 
using enzymatic and colorimetric assays.  Circulating hormones, including insulin, GIP, 
GLP-1, adiponectin, and leptin were also determined using validated enzyme-linked 
immunosorbent assay (ELISA) techniques for canine samples.  Mercodia Porcine Insulin 
ELISA (Mercodia AB, Uppsala, Sweden) was used for insulin analysis according to 
Bennet et al. and Sato et al. (Bennet et al., 2000; Sato et al., 2002).  Gastric Inhibitory 
Peptide (Human) EIA Kit (Phoenix Pharmaceuticals, Inc., Belmont, CA) was 
appropriately validated by spiking with standard GIP and by serial dilution techniques, 
and used for GIP analysis.  Glucagon-Like Peptide-1 (Active) ELISA Kit (Linco 
Research, St. Charles, MO) was used for GLP-1 analysis (Nathan et al., 1992).  The 
GLP-1 sequence is highly conserved between species, with no sequence variation 
occurring at all in mammals.  Plasma adiponectin concentrations were measured using 
the overnight fasting samples and appropriately validated ELISA methodology (Ishioka 
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et al., 2002a; Ishioka et al., 2006).  Adiponectin (Murine/Rat) ELISA kit (Otsuka 
Pharmaceutical, Co. Ltd., Tokyo, Japan) was used for adiponectin analysis which was 
performed in Dr. Ishioka’s laboratory (Nihon Veterinary and Animal Science University, 
Tokyo, Japan).  Plasma leptin concentrations were measured using the overnight fasting 
samples and conducted by the procedure of Iwase et al. (2000), and appropriately 
validated by the procedure of Ishioka et al. (2002c) and was also performed by Dr. 
Ishioka. 
A microplate spectrofluorometer (Gemini EM: Molecular Devices Corporation, 
Menlo Park, CA) and its software (Softmax Pro ver. 5.0, Molecular Devices Corporation, 
Sunnyvale, CA) were used to determine GLP-1 concentrations, and a kinetic microplate 
reader (UV max: Molecular Devices Corporation, Menlo Park, CA) was used for the 
other parameters. 
Statistical analyses 
 Data are expressed as means ± SEM.  Statistical analyses of all data were 
performed using repeated measures ANOVA, to test for main effects of time and diet as 
well as the interaction of time with diet, and significance was set at P < 0.05.  Tukey test 
was used as a post-hoc test for multiple comparisons for main effects of diet, time, and 
diet x time interactions, at a level of significance of P < 0.05.  All data were found to 
follow a Gaussian distribution at P < 0.05 using the Kolmogorov-Smirnov (KS) test.  All 
statistical tests were performed using GraphPad Prism version 4.00 for Macintosh 
(GraphPad Software, San Diego, CA, www.graphpad.com). 
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Results 
Weight loss, kcal consumption, and diet digestibility 
 During the acclimation period, all dogs had been fed the chicken by-product meal 
based, gruel-type diets containing a 50/50 (w/w) blend of canola and soybean oils and a 
50/50 (w/w) blend of the HGIS and LGIS starches for 4 weeks.  During this time, average 
body weights of each obese dog were used to estimate the number of calories needed for 
each dog to maintain its obese body weight (ca. 900 - 1100 kcal range) and this amount 
was fed during the weight loss periods.  However, during the experimental period, the 
dogs voluntarily consumed only 68% ± 4 (SEM) % of the diet amounts offered on a 
weight basis.  Thus, it was not unexpected that all dogs lost weight under this condition.  
Nonetheless, when the change in body weight was considered vs. time among the four 
groups, it was found that dogs fed the LGIS diets lost a larger percentage of their starting 
obese body weights than those fed the HGIS diets independent of oil type (Figures 4 and 
5).  For that matter, the LGIS diet groups lost approximately 2.0% body weight per week 
while the HGIS diet groups lost only 1.0%.  Reasons for this difference were ascertained 
from the results of the digestibility studies of the diets.  It was found that the total 
metabolizable energy of the LGIS diets was considerably lower than that of the HGIS 
diets (Table 2).  Thus even though the dogs had consumed similar amounts of the diets on 
a weight basis, the amounts of ME ingested overall differed between the two starch types 
(Figures 6 and 7).  Furthermore, the digestibility studies revealed significant differences 
between the two starch types and a modest, but not significant digestibility difference in 
protein (Figure 7).  Dietary fat digestibility remained high in all diets at approximately 
96%. 
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Figure 4.  BW changes during weight loss period.  Values are mean ± SEM.  Letters not 
in common for a time point denote significant differences among diets by repeated 
measures ANOVA, P < 0.05. 
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Figure 5.  Comparison of BW changes vs. kcal consumption. (A) LGIS/DAG (B) 
LGIS/TAG.  Bars (kcal consumed) and line (percent body weight change) are 
indicated.  Values are mean ± SEM. 
  
39 
(C)
0 1 2 3 4 5 6 7 8 9 10
0
200
400
600
800
1000
1200
-30
-25
-20
-15
-10
-5
0
5
Weeks
(D)
0 1 2 3 4 5 6 7 8 9 10
0
200
400
600
800
1000
1200
-30
-25
-20
-15
-10
-5
0
5
Weeks
 
Figure 5.  (continued).  (C) HGIS/DAG (D) HGIS/TAG.  Bars (kcal consumed) and line 
(percent body weight change) are indicated.  Values are mean ± SEM. 
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Figure 6.  Mass and kcal amounts of diets consumed.  Values are mean ± SEM.  Letters 
not in common for a kcal amount denotes significant differences among diets by 
repeated measures ANOVA, P < 0.05. 
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Figure 7.  Digestibilities of each treatment diet.  Values are mean ± SEM.  Letters not in 
common for a nutrient denote significant differences among diets by repeated 
measures ANOVA, P < 0.05. 
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Total diet digestibilities were LGIS/DAG, 79.8 + 5.0%; LGIS/TAG, 82.1 + 4.3%; 
HGIS/DAG, 95.0 + 3.0%; and HGIS/TAG, 93.7 + 4.5% (mean + SEM). 
Plasma glucose 
At both wk 1 and 8, no significant differences due to diet were seen among post-
prandial plasma glucose concentrations although the expected time effect (P < 0.05) was 
noted in all groups (Figure 8). 
Plasma TG 
Diet effects were found for plasma triacylglycerol at both wk 1 and 8 (Figure 9).  
At wk 1, DAG diet groups decreased post-prandial TG concentrations compared with 
TAG diet groups.  Peak values of TAG diet groups appeared at 180 min, while peak 
values of DAG diet groups tended earlier.  Increased plasma TG were seen only in the 
LGIS/TAG diet group at 60 min.  Post-prandal TG lowering was observed with only the 
combination of LGIS/DAG diet. The peak values of the TAG diet groups tended earlier 
in wk 8 than wk 1, whereas the peak values of the DAG diet groups tended later in wk 8 
than wk 1. 
Plasma NEFA 
At both wk 1 and 8, all diet groups showed decreased post-prandial NEFA 
concentrations.  However, the LGIS group decreased NEFA less than the HGIS groups.  
These differences became less pronounced at wk 8.  Generally, plasma NEFA 
concentrations were initially depressed in all groups at both 15 and 30 min.  This 
lowering effect was statistically significantly different when the LGIS and HGIS diet 
groups were compared (Figure 10) with significantly less lowering occurring when the 
LGIS diets were fed. 
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Figure 8.  Post-prandial plasma glucose concentrations.  (A) week 1 and (B) week 8.  A 
significant time effect was observed but no significant diet differences.  Values are 
mean ± SEM. 
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Figure 9.  Post-prandial plasma TG concentrations.  (A) week 1 and (B) week 8.  Values 
are mean ± SEM.  Letters not in common for a time point denote significant 
differences among diets by repeated measures ANOVA, P < 0.05. 
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Figure 10.  Post-prandial plasma NEFA concentrations.  (A) week 1 and (B) week 8.  
Values are mean ± SEM.  Letters not in common for a time point denote significant 
differences among diets by repeated measures ANOVA, P < 0.05. 
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Plasma insulin 
Post-prandial changes in insulin concentrations included expected time effects at 
both wk 1 and wk 8 but diet effects were also observed (Figure 11).  At wk 1, statistically 
significant increases of plasma insulin were observed with HGIS diet groups compared 
with LGIS diet groups.  At wk 8, insulin peak values of all diets were observed at 120 
min but some blunting of this response had occurred such that the diet effect was less 
marked compared with wk 1.  At both wk 1 and 8, plasma insulin was significantly lower 
in the LGIS diet groups even though glucose concentrations were similar among all 
groups (Figure 8). 
Plasma GIP 
At both wk 1 and 8, plasma GIP concentrations increased in all diet groups and 
statistically significant time effects (P < 0.05) were seen at 60 min post-prandially 
(Figure 12).  At wk 1, LGIS diet groups tended toward lower GIP concentrations 
compared with HGIS diet groups but these differences were modest.  Peak values 
appeared at 30 min, leveling off at 60 min.  At wk 8 differences among diets, especially 
starch effects, became more prominent.  Peak GIP values with LGIS groups again 
appeared at 30 min then leveled off while the HGIS diet group values continued to 
increase at 60 min.  A statistically significant diet effect was also noted at 60 min with 
increased GIP concentrations in the HGIS/DAG diet group compared to the other 3 diets 
(Figure 12).  Finally, a positive linear correlation between insulin and GIP was observed 
(week 1) which was statistically significant at 15 and 30 min post-prandially (Figure 13). 
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Figure 11.  Post-prandial plasma insulin concentrations.  (A) week 1 and (B) week 8.  
Values are mean ± SEM.  Letters not in common for a time point denote significant 
differences among diets by repeated measures ANOVA, P < 0.05. 
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Figure 12.  Post-prandial plasma GIP concentrations.  (A) week 1 and (B) week 8.  
Values are mean ± SEM.  Letters not in common for a time point denote significant 
differences among diets by repeated measures ANOVA, P < 0.05. 
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Figure 13.  Correlations between plasma insulin and GIP.  15, 30, and 60 min.  R-
squared and P-values are indicated. 
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Plasma GLP-1 
At wk 1, plasma GLP-1 concentrations increased in all diet groups but differences 
among the diet groups were not seen.  At wk 8, differences among the diet groups 
became varied.  Peak values of LGIS/TAG diet group appeared at 15 and 60 min while 
the HGIS/DAG diet group had significantly higher concentrations than the other diet 
groups at these times (Figure 14).  Statistically significant time effects were seen at both 
wk 1 and 8 at the 60 min post-prandial time periods.  However, main effects of diet on 
GLP-1 were not observed in this study. 
Plasma adiponectin 
Fasting plasma adiponectin concentrations were significantly higher in the 
LGIS/DAG diet group compared with all other diet groups (Figure 15).  LGIS diet groups 
increased plasma adiponectin concentrations with time (i.e., weight loss), whereas HGIS 
diet groups tended lower over time.  However, correlations of adiponectin and body 
weight were not observed during the experimental period (Figure 16) 
Plasma leptin 
Significantly lower plasma leptin concentrations were found, consistent with 
weight loss, in all groups, especially the LGIS/DAG diet group (Figure 15).  Positive 
correlations of leptin and body weight were also found during the experimental period 
(Figure 16).  Correlations between leptin and adiponectin were not observed (Figure 17). 
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Figure 14.  Post-prandial plasma GLP-1 concentrations.  (A) week 1 and (B) week 8.  
Values are mean ± SEM.  Letters not in common for a time point denote significant 
differences among diets by repeated measures ANOVA, P < 0.05. 
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Figure 15.  Fasting plasma (A) adiponectin and (B) leptin concentrations.  Values are 
mean ± SEM.  Letters not in common for a time point denote significant differences 
among diets by repeated measures ANOVA, P < 0.05. 
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Figure 16.  Correlations between plasma (A) adiponectin / (B) leptin and BW.  R-
squared and P-values are indicated. 
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Figure 17.  Correlations between plasma adiponectin and leptin.  R-squared and P-values 
are indicated. 
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Discussion 
 All dogs lost body weight during this study.  The primary reason for this effect 
is that, on average, the dogs voluntarily consumed approximately 68% of the total 
calories offered them on a daily basis.  In veterinary practice, canine obesity is treated 
using diet management techniques designed to reduce daily calorie intake by 
approximately 35 to 40% of the amount that would maintain that particular animal’s ideal 
body weight.  In the present setting, dogs were offered the number of calories calculated 
to maintain their obese weights (ca. 950 kcal/d).  However, as noted, only 68% of these 
calories were ingested by the dogs (ca. 500 to 700 kcal range).  This would compare to 
about 550 kcal which is approximately 65% of the number of calories to maintain the 
animals’ average ideal weights were they presented in their obese state to a veterinary 
practice (i.e., 65% of ME = (0.65) 130 (12 kg)0.75 = 544 kcal).  Because the dogs lost 
from 1.0 to 2.0% body weight per week (a typical clinical weight loss target), these data 
help validate the approach used in veterinary practice as all dogs remained healthy and 
active during the experiment while successfully losing weight. 
 When the change in body weight was considered vs. time among the four 
groups, dogs fed the LGIS diets lost a larger percentage of their starting obese body 
weights than those fed the HGIS diets.  As noted, the total ME of the LGIS diets were 
considerably lower than that of the HGIS diets even though dogs consumed the same 
amounts of diet on a dry weight basis.  Thus dogs had consumed lower amounts of ME 
overall yet were not denied having a larger volume of food in their daily meal, thereby 
potentially contributing to satiety.  The reason for this difference was primarily because 
digestibility of the LGIS was significantly lower than the HGIS, while fat types were not 
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different, and protein was only modestly different.  Thus total digestibilities of the LGIS 
diets were less than the HGIS diets. 
 In addition to more weight loss, a second benefit of LGIS diets is that they 
resulted in a significant reduction of circulating insulin when measured over time in 
response to a mixed meal while glucose concentrations were similar in all groups.  This 
insulin effect was most prominent early on during this diet study (wk 1) and not as 
marked at wk 8.  Consequently there appeared to be some adaptation to this dietary 
component with time.  Even though these effects were independent of dietary oil type, 
other distinct advantages of the DAG oil, when combined with the LGI starch, in a mixed 
diet were observed.  As mentioned, the insulin effect appeared to occur more prominently 
early during the weight loss period.  By contrast, DAG oil effects appeared to be more 
pronounced later in the experiment (i.e., wk 8).  Thus, significant post-prandial 
triacylglycerol lowering was observed with the DAG/LGIS compared to the TAG/LGIS 
combination especially at wk 8.  And also, both at wk 1 and 8, increased post-prandial 
TG concentrations was observed with LGIS/TAG diet especially early on.  It is well 
known that insulin enhances LPL activity in adipocytes.  Less insulin environment with 
LGIS diet also cause less LPL activity so that relatively higher plasma concentrations of 
TG was observed compared with HGIS diet groups.  Post-prandial NEFA concentrations 
were decreased less with the LGI starch containing diets at week 8.  It has reported that 
decreased insulin levels promote HSL activity and lipolysis (Van Harmelen et al., 1999).  
With the LGI starch, if glucose flux into cells had been decreased as a result of an 
attenuated insulin response, then relatively more tissue lipolysis from storage sites would 
be favored, resulting in fatty acid mobilization and the NEFA elevations observed.  An 
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attenuated release of insulin with LGI starch may also result in less active utilization of 
circulating NEFA.  Taken together, these lipid metabolite changes support the possibility 
of lower TAG entering the bloodstream after eating (DAG effect) while increased relative 
amounts of NEFA were available for energy in a lower insulin environment (LGIS effect) 
and while maintaining glucose homeostasis.  Thus, the findings of lower digestibility, 
increased but safe rate of weight loss, effective loss of percent body fat, improved insulin 
response and lower post-prandial TG concentrations demonstrates that the DAG oil and 
LGI starch combination is preferred for weight loss in this canine model. 
 Although no diet differences were observed in circulating GIP concentrations at 
week 1, the positive linear correlation of all diet group data between circulating insulin 
and GIP at 15 and 30 min post-prandially is consistent with the known stimulating effect 
of GIP on insulin secretion. 
 Because GIP secretary cells are more abundant in the upper part of the small 
intestine (Damholt et al., 1999), it follows that there would be an early post-prandial 
insulin stimulatory effect as seen in the present study (i.e., at 15 and 30 min). 
 When the diets were fed for a longer period (i.e., 8 wk), it appeared that the 
intestinal cells of animals fed the HGIS diets continued to secrete amounts of GIP post-
prandially further adding to a more sustained insulinotropic effect.  Indeed circulating 
insulin levels were significantly higher in the HGIS diets compared with the LGIS diet 
groups.  It remains to be seen whether a longer post-prandial sampling period would 
additionally verify this latter possibility. 
 Effects of another insulin secretagogue, GLP-1 was less notable in this study.  
No effects of diet on GLP-1 were noted yet time effects, post-prandially, were found for 
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this polypeptide hormone in the circulation.  It should be noted that the determination of 
circulating levels of GLP-1 does not allow the direct assessment of the actions of GLP-1 
in which numerous interactions among paracrine, endocrine, neural, and luminal 
influences may exist at the cellular level.  Nonetheless, it is noteworthy that while a 
relationship between GIP and insulin was observed, this was not the case for GLP-1.  GIP 
has insulinotropic activity and is believed to be released from the upper gut while GLP-1 
is released from the lower gut and has a glucagon-lowering effect.  An 
immunocytochemical study revealed the exact locations of GIP and GLP-1 producing 
cells in the dog (Damholt et al., 1999).  GIP - secreting K cells were equally distributed in 
duodenum and jejunum, with the GLP-1 - secreting L cells concentrated in the jejunum 
(5% duodenum, 73% jejunum and 22% ileum).  This study also found that the middle 
section of the small intestine containing 69% of the K cells also contained 51% of the L 
cells, and over 30% of the L cells in this region were found adjacent to K cells. 
 It has been reported that glucose does not directly stimulate canine L cells 
(Damholt et al., 1998).  It is more probable that glucose releases GIP from the upper 
intestine that, in turn, stimulates GLP-1 secretion.  Damholt et al. concluded that the 
ability of GIP to stimulate GLP-1 secretion is probably mediated through activation of 
protein kinase A.  In the present study, the sampling schedule used (0 to 60 min) may not 
have been long enough to see any substantial changes in GLP-1 although a significant 
time effect was found during the post-prandial period studied.   
 Also, species differences have been reported using isolated perfused ileal 
segments from dog and rat (Manaka et al., 1996).  It was found that GLP-1 release 
occurred when rat segments were perfused with GIP but not when dog segments were 
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studied.  They concluded that GLP-1 release in rat, but not in dog, is modulated by GIP, 
the upper GI tract factor, and that the discrepancy in GLP-1 response to GIP might be due 
to species differences.  Obviously numerous other factors may influence the increase of 
GLP-1 post-prandially in dogs; however, in the present study, changes in canine post-
prandial plasma insulin and GIP do not appear be associated with changes in GLP-1 
concentration during the first 60 min post-prandially. 
 Finally, plasma adiponectin concentrations observed in the present study were 
significantly higher in the LGIS/DAG diet group compared with all other diet groups.  
Even though we did not observe a significant inverse correlation between adiponectin and 
body weight, the changes seen were consistent with weight loss.  In addition, we did not 
observe an inverse correlation between adiponectin and leptin.  By contrast in humans, 
blood adiponectin concentration negatively correlates with the degree of obesity and is 
lower in obese individuals (Havel, 2004; Matsuzawa et al., 2004).  In dogs, it has 
reported that blood leptin concentrations were dramatically altered by fasting compared 
to those seen a few hours after feeding (Ishioka et al., 2005), whereas blood adiponectin 
concentration was nearly unchanged (Peake et al., 2003).  Ishioka et al. (2006) also noted 
that while plasma adiponectin can be an additional marker of adiposity in dogs, it is a less 
sensitive obesity index compared with leptin.  Brunson et al. (2007) reported that 
adiponectin gene expression and protein secretion are unaffected in a high-fat fed, obese 
dog model.  They concluded that plasma adiponectin concentrations in dogs are 
differently regulated compared to obese humans.  Even though the dogs lost an 
appreciable amount of weight, body fat, and decreased their BCS from 8.4 to 7, either the 
relative amounts of weight lost or the short term of the present experiment may help 
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explain the lack of correlation of adiponectin with weight loss or with leptin seen in the 
present study. 
 In this study, we observed significantly lower plasma leptin concentrations in all 
diet groups, especially the DAG/LGIS diet group.  Also a positive correlation between 
leptin and body weight was observed.  These findings are similar to these of other 
investigations (Ishioka et al, 2002a; Ishioka et al., 2007), and it is concluded that leptin 
concentration is consistent with weight loss and may be a more reliable marker than 
adiponectin in dogs as in humans and rodents.
  
61 
CHAPTER IV 
UCP2 GENE EXPRESSION IN CANINE DUODENAL EPITHELIUM 
 
Introduction 
 The uncoupling proteins (UCPs) are members of the mitochondrial transporter 
family that dissipate the mitochondrial proton gradient as heat more than via ATP 
synthesis (Cadrin et al., 1985; Cannon et al., 1982).  They are roughly divided into 3 
subtypes and show high homologies with each other.  UCP1, a so called mitochondrial 
carrier protein, is seen exclusively in brown adipose tissue (BAT) which is the major site 
of regulatory thermogenesis in small rodents.  UCP2 is widely located in most tissues 
studied in human and rodents including white adipose tissue (WAT) and skeletal muscle, 
which is thought to be the major thermogenic organ in large animals including humans 
(Boss et al., 1998).  UCP3 is expressed mainly in skeletal muscle in humans, and BAT 
and skeletal muscle in rodents (Boss et al., 1998).  The UCPs reduce the mitochondrial 
membrane potential via a characteristic uncoupling activity and may be involved in the 
regulation of thermogenesis and energy expenditure to greater or lesser degrees (Klaus et 
al., 1991; Cannon and Nedergaard, 1985).  Although all subtypes are considered to have 
mitochondrial uncoupling activity, it has been reported that the main and prominent 
function of UCP1 is thermoregulation.  By comparison, UCP2 is involved in the control 
of reactive oxygen species (ROS) generation and UCP3 in the handling of lipids as fuels 
(Ledesma et al., 2002). 
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 In rats, both short and long term studies have shown that high protein diets up-
regulate hepatic UCP2 mRNA gene expression.  Thus, UCP2 mRNA expression is 
related to the level of dietary protein intake (Petzke et al., 2005; Petzke et al., 2007).    
 According to Murase et al. (2002), a study in obesity-prone C57BL/6J mice fed a 
diet high in DAG compared with TAG resulted in significant decreases in body weight 
and lower feed efficiencies.  In addition, UCP2 mRNA expression in the small intestine 
also increased.  Several studies of the UCPs have been reported in small animals and 
humans, but only a few canine reports exist (Ishioka et al., 2002b).  Thus, it is of interest 
to determine whether dietary DAG results in increased UCP2 gene expression during 
canine weight loss consistent with the observations of Murase et al. (2002) in mice. 
Preliminary study 
 Our preliminary study provided some useful information on the above question.  
Three normal, sexually intact adult female beagles, all 5 yr old, with body condition 
scores of 5 on a 9 point scale, where 5 is ideal, were used in the study.  The dogs were 
individually housed in approved sized kennels with 12 h light cycles, allowed free access 
to water and exercise, and fed free choice during the entire 6 weeks of study. 
 A 6-wk experimental period was used; divided into three stages (two weeks each).  
For the first 2 wk, all dogs were fed a premium quality pet food (Hill’s Science Diet, 
Adult Original. Hill’s Pet Nutrition, Inc., Topeka, KS) to establish a baseline (stage 1).  
After this period, dogs were fed the same diet containing TAG for 2 weeks (stage 2).  In 
the last 2 weeks, dogs were fed the same diet containing DAG (stage 3).  At the end of 
each stage, tissue samples from duodenal epithelium were obtained via endoscopic 
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biopsy under general anesthesia (see below for techniques used) and used for UCP2 
analysis. 
 Our results showed that the TAG containing diet tended to lower UCP2 gene 
expression in the small intestine compared with DAG containing diet, and DAG 
containing diet seemed to increase UCP2 gene expression, but no statistically significant 
difference was observed. 
 To further extended this observation, we investigated how longer-term feeding of 
different DAG and TAG containing diets affect UCP2 mRNA expression in canine small 
intestine.  For this purpose, diets containing either DAG or TAG and either LGIS or 
HGIS were compared during weight loss.  The number of the dogs we used in this study 
was also increased (n = 6 per diet group) compared with our preliminary study (n = 3). 
Materials and Methods 
Animals 
 The protocol for this study was approved by the Texas A&M University 
Laboratory Animal Care Committee (AUP # 2004-202: Molecular biology of 
uncoupling protein).  All dogs were housed at the Laboratory Animal Research and 
Resources (LARR) facility, Texas A&M University and individually maintained in 
kennels according to the American Physiological Society Guidelines for Animal 
Research and according to guidelines set forth by Texas A&M University Care and Use 
Committee.  Prior to entering the study, all dogs had complete blood counts and serum 
biochemistry profiles tests performed to assure normal clinical status.  All dogs used in 
the study appeared to be clinically and physiologically normal. 
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 Twelve obese, sexually intact adult female beagles, ages 2 to 6 yr old, with body 
condition scores of  8 to 9 on a 9 point scale, where 5 is ideal, were used.  All dogs were 
individually housed in approved sized kennels with 12 h light cycles, allowed free access 
to water and exercise, and fed free choice during the study.  All dogs were randomly 
divided into one of the four dietary groups assigned (n = 3 per diet group).  The dogs 
were assigned to the diet groups to minimize bias with respect to age, BCS, and body fat 
content. 
Diets and feeding 
 Four diets were evaluated.  The diets were combinations of: LGIS/DAG; 
LGIS/TAG; HGIS/DAG; and HGIS/TAG.  Ingredients of these diets included chicken 
by-product meal; either high amylose corn (LGI) or waxy corn (HGI) starches that had 
been gelatinized, either TAG or DAG enriched dietary oil, and appropriate mineral and 
vitamin pre-mixes suitable for canine maintenance.  On a percent metabolizable energy 
basis, the diets contained: 25% protein, 38% fat and 36% nitrogen-free extract (NFE), 
approximately.  The diets were isocaloric at approximately 4200 kcal/kg.  All diets are 
described in Appendix A and also in the previous chapter.  An experimental weight loss 
period of 10 weeks was used.  During weeks 9 and 10, biopsies were taken from one dog 
from each diet group using a Monday/Wednesday/Friday sequence until all dogs had 
been biopsied.  All dogs were fasted overnight, anesthetized, and tissue was collected via 
endoscopic biopsy (Olympus America Inc., Center Valley, PA).  All dogs were 
administered the following medication to conduct these procedures: glycopyrrolate as 
pre-anesthetic medication, propofol for induction, and isoflurane to maintain general 
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anesthesia.  Approximately 1 g of tissue specimens were collected immediately from a 
duodenal epithelial site, snap-frozen in liquid nitrogen and stored at -80°C for 
subsequent RNA isolation. 
 After the 10 wk weight loss regimen was completed, all dogs were again fed the 
commercial diet, oil, and cookies for 16 weeks in order to attain their initial levels of 
obesity (re-induction of obesity).  All dogs were then assigned to a treatment diet exactly 
opposite to the one they had been fed during the first period of the study and fed for 10 
weeks to repeat the study design.  In this way, an n = 6 sample size was obtained for 
each diet group.  Tissue samples collected were used for UCP2 mRNA gene expression 
analysis as described below. 
Preparation and analysis of RNA 
 Each tissue sample was thawed and homogenized using an ultrasonic 
homogenizer (Model 300 V/T, BioLogics Inc., Manassas, Virginia) and total RNA was 
extracted using TRIzol (Gibco BRL, Grand Island, NY) according to the manufacturer’s 
instructions.  Extracted total RNA was purified by appropriate procedures as follows; 
serial extractions with chloroform, isopropyl alcohol, and 75% and absolute ethanols.  
Yield and purity were quantified by measurement of absorbance at 260 and 280 using a 
spectrophotometer (DU7400 diode array spectrophotometer, Beckman Coulter, Inc., 
Fullerton, CA).  Purified total RNA (5 µg) extracted from the duodenal epithelium were 
blotted onto positive charged nylon membrane, Hybond-N+ (GE Healthcare UK 
Limited, Buckinghamshire, UK), using a Minifold II Slot Blot System (Schleicher & 
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Schuell, Inc., Keene, NH), baked in an incubator for 20 min at 80°C, sealed, and stored 
in the freezer until the time of the analysis. 
Extracted total RNA were reverse transcribed (RT) using AMV Reverse 
Transcriptase (USB Corporation, Cleveland, Ohio) and oligo-dT primer linked to an 
adapter sequence (Adapter + T15).  Polymerase chain reaction (PCR) was performed 
with a cDNA template and primers designed from the reported sequences (Ishioka et al., 
2002b).  UCP2 and 36B4 primers were purchased from Integrated DNA Technologies 
(IDT, Coralville, IA) and were as follows: UCP2 (Forward primer (murine 1-) 5’- ATG 
GTT GGT TTC AAG GCC AC -3’, Reverse primer (canine - 640) 5’- GGT CAT CTG 
TCA TGA GGT TG -3’), 36B4 (Forward primer (canine 1-): 5’- TGG AAA TCC AAC 
TAC TTC CTT AAG -3’, Reverse primer (canine - 787): 5’- CAG CAA GTG GAA 
AGG TGT AAT CAG T -3’).  PCR was conducted for 35 cycles at 94°C for 1 min, at 
55°C for 1 min and at 72°C for 1 min in a solution (50 µL) of 10 µmol of each primer 
and 2 units of rTaq DNA Polymerase (GE Healthcare UK Limited, Buckinghamshire, 
UK).  The PCR products were sequenced using Progene (Techne (Cambridge) LTD., 
Cambridge, UK).  For probes, cDNA of UCP2 and 36B4 was electrophoresed in a 2.0 % 
agarose gel, purified using GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare UK Limited, Buckinghamshire, UK). 
Purified RNA was labeled using AlkPhos Direct Labeling and Detection System 
with CDP-Star (GE Healthcare UK Limited, Buckinghamshire, UK) according to the 
manufacturer’s instructions. The probes were hybridized to the blotted membranes for 
18 h at 55°C.  Rinsed membrane for all probes were placed and exposed to KODAK 
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BioMax MS Film (KODAK Industrie, Cedex, France) for 2 to 8 h to obtain optimal 
images.  To determine the intensities of the bands, films were scanned and analyzed with 
an imaging densitometer (Model GS-700, Bio-Rad, Hercules, CA) and ImageJ 1.38x 
(NIH, National Institute of Health, USA).  For normalization, 36B4 (acidic ribosomal 
phosphoprotein) mRNA was used and the UCP2 mRNA levels were calculated relative 
to the 36B4 mRNA levels. 
Statistical analyses 
Data are expressed as means ± SEM.  Statistical analyses of all data were 
performed using repeated measures ANOVA, to test for main effects of time and diet as 
well as the interaction of time with diet, and significance was set at P < 0.05.  Tukey test 
was used as a post-hoc test for multiple comparisons for main effects of diet, time, and 
diet x time interactions, at a level of significance of P < 0.05.  All data were found to 
follow a Gaussian distribution at P < 0.05 using the Kolmogorov-Smirnov (KS) test.  All 
statistical tests were performed using GraphPad Prism version 4.00 for Macintosh 
(GraphPad Software, San Diego, CA, www.graphpad.com). 
Results 
 Although there were no statistically significant differences, UCP2 mRNA levels of 
the LGIS diet groups tended to be lower compared with the dogs in the HGIS diet 
groups (Figure 18).  This starch effect was unexpected.  By contrast, differences between 
DAG and TAG diet groups were not observed in either of the LGIS and HGIS diet 
groups as was hypothesized.  Our results indicated that combinations of LGI starch and  
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Figure 18.  UCP2 gene expression in the duodenal epithelium.  The amounts of UCP2 
mRNA were calculated relative to the 36B4 mRNA levels.  Values are the means ± 
SEM of six animals. 
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oils decrease the UCP2 mRNA expression in the canine small intestine compared with 
the diet combinations of HGI starch and oils. 
Discussion 
 Although numerous UCP studies in humans and animals have been reported, only 
a few canine reports exist (Ishioka et al., 2002b).  In general, UCP2 is ubiquitously 
expressed in most tissues in humans and rodents (Dullo and Samec, 2001).  In dogs, 
Ishioka et al. (2002b) reported that UCP2 mRNA was expressed in most tissues as well, 
and is particularly abundant in adipose tissue, spleen and lung.  In this study, we used 
duodenum epithelium.  According to Murase et al. (2002), dietary DAG stimulates 
UCP2 gene expression in the small intestine in mice.  It is reasonable to examine the 
small intestine because it is the first and most susceptible organ exposed to dietary fat. 
 GAPDH has been used primarily to normalize gene expression.  In this study, we 
used 36B4 (acidic ribosomal phosphoprotein) to calculate the UCP2 mRNA levels.  This 
was because we adjusted the conditions to Murase’s study (Murase et al., 2002). 
 Several factors influencing UCP2 gene expressions have been reported (Boss et 
al., 1998; Diehl and Hoek, 1999).  UCP2 expression is generally increased in situations 
of oxidative stress, in which circumstance UCP2 would protect cells by limiting 
mitochondrial ROS production therefore preventing the onset of apoptosis (Diehl and 
Hoek, 1999). Significant positive correlations have also been reported between UCP2 
mRNA levels in WAT and body mass index (BMI) in humans (Millet, et al., 1997). 
 Boss et al. (1998) suggested in a review article that UCP2 is expressed in 
pancreatic islets and might, by decreasing cellular ATP levels, blunt glucose-induced 
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insulin secretion.  And leptin, which decreases the insulin response to glucose and other 
fuels, was found to increase UCP2 mRNA expression in pancreatic islets (Koyama et al., 
1997; Zhou et al., 1997).  Thus, Boss et al. hypothesized that a high level of UCP2 could 
decrease insulin secretion (Boss et al., 1998). 
 In our study, lower plasma insulin was observed with the LGIS diet groups 
compared with HGIS diet groups while glucose concentrations were similar among all 
groups.  Our results also show that higher plasma leptin concentrations were observed in 
HGIS diet groups compared with LGIS groups.  These findings are similar to the 
hypothesis of Boss et al. (1998). 
 It has also been reported that UCP2 mRNA expression is enhanced by PPARγ 
agonists in rats pancreatic islets (Shimabukuro et al., 1997).  Boss et al. (1998) also 
hypothesized that increased levels of NEFA in pancreatic islet cells may enhance UCP2 
expression, and in turn, impair insulin secretion.  The effect of NEFA on UCP2 gene 
expression might be mediated by PPARγ (Boss et al., 1998).  This potential NEFA effect 
was not supported in the present study.  Our results indicated that lower plasma NEFA 
concentrations were observed in HGIS diet groups compared with LGIS groups which is 
opposite to the speculation of Boss et al. (1998).  However, differences in NEFA 
concentrations may exist in plasma vs. pancreatic islet cells during feeding.  Our NEFA 
changes were observed post-prandially while the intestinal biopsies were obtained in the 
fasted state. 
 In addition, our results show that the 1,3-DAG diets did not stimulate UCP2 gene 
expression in the canine small intestine.  We observed a more prominent starch effect 
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than oil effect.  Although there was no significant difference among the diet groups, the 
combinations of LGI starch and DAG/TAG tended to lower UCP2 gene expression in 
the small intestine compared with the diet combinations of HGI starch and DAG/TAG.  
This effect was unexpected.  There are some reports in rodents regarding protein and fat 
on UCP2 gene expressions (Petzke et al., 2005; Petzke et al., 2007), but no information 
is available as to the relationship with carbohydrate and UCP2 gene expression in 
rodents or, for that matter, in dogs. 
 From the above information, we speculate that the long term consumption of a 
LGIS diet mediated decrease of UCP2 mRNA expression may be a metabolic down 
regulation.  First of all, the LGIS diet groups had lower digestibilities.  The associated 
lower metabolizable energy also resulted in more body weight loss compared with the 
HGIS diets.  In this case, in the face of lowered energy intake from the LGIS diets 
during weight loss, UCP2 may reduce its uncoupling activity and thus favor relatively 
more ATP production than heat generation.  Less expression of UCP2 in canine small 
intestine may thus protect the non-obese state under conditions of moderate and/or 
insufficient energy intake and may also play an adaptive role during down regulation of 
energy metabolism with weight loss.  In this way, intestinal UCP2 upregulation may be 
involved in the well known thermal effect of feeding and possibly be down regulated 
during starvation to conserve energy via favoring ATP production.  A study utilizing 
simple caloric restriction in UCP2 mRNA expression may further clarify this possibility.  
Alternatively, the possibility also exists that decreased UCP2 mRNA expression may be 
due, at least in part, to the decrease leptin concentrations seen with the LGIS diets.  
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Indeed, Koyama et al. found that leptin increased UCP2 mRNA expression in pancreatic 
islet cells.  Thus it can be hypothesized that the HGIS diet associated increase in leptin 
may be associated with increased small intestinal UCP2 mRNA expression as well. 
 Although unknown at this time, species differences regarding UCP2 expression 
may also exist as may be the case in the GLP-1 data between dogs and mice (Manaka et 
al., 1996).  Finally any potential oil effect in canine intestine may be less sensitive or not 
strong enough to surpass the starch or total calorie restriction effects seen on UCP2 gene 
expressions compared with mouse intestine. 
 Because there are no previous canine reports examining the effects of DAG and 
LGI starch on UCP2 mRNA expression, this study is the first to do so.  Although further 
investigation is required, it has provided interesting data in the dog and may lead to 
additional hypothesis regarding UCP effects on energy metabolism. 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
Obesity is the most common nutritional disorder in small animal medicine 
closely related to the mortality and morbidity of various diseases.  Decreasing the 
incidence of obesity is considered to be a most important way to maintain health, prevent 
disease, and contribute to longevity.  Diet therapy using low glycemic index starch 
(LGIS) and diacylglycerol (DAG) may be a reasonable obesity management tool without 
food restriction, forced physical activity, and impairment of health. 
The overall objectives of this dissertation were to investigate lipid and 
carbohydrate modification with the combination of diacylglycerol (DAG) and low 
glycemic index starch (LGIS) in obese canine during weight loss.  We hypothesized that 
the combination of DAG and LGI carbohydrate may support more efficient and healthy 
weight loss in beagles along with the improvement of biochemical and hormonal 
biomarkers.  Also, UCP2 gene expressions in small intestine was also evaluated for this 
purpose. 
To conduct this study, obesity was initially induced/re-induced in all beagles.  
All dogs were initially fed twice their daily calculated number of calories 
(2×125(BWkg)0.75) using a combination of dry extruded commercial pet food and 50/50 
(w/w) blend of canola and soy bean oils (40 g/d).  After 3 wk, all dogs were fed this 
mixture along with 5 Pecan shortbread cookies for the next 16 wk (obesity induction 
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period: wk 4 to 19).  The major findings of this initial study can be summarized as 
follows: 
 A significant increase of food efficiency was observed during the obesity re-
induction period compared with the obesity induction period.  It was found that once 
body weights of obese dogs had been reduced, fewer calories were needed to regain the 
obese steady state.  For that matter, the rate of weight gain was greater at an even lower 
calorie intake during re-induction of obesity.  These results demonstrate the effects of 
yo-yo dieting on energy metabolism resulting in the rapid regain of body weight after 
successful weight loss.  Results also suggest that metabolic “down-regulation” of energy 
needs with weight loss regimens continues after target weights have been achieved. 
 Human snack foods appeared to stimulate appetite and increase the overall net 
calorie consumption of the total ration.  They provide a calorie dense dietary supplement 
leading to the rapid induction of an obese steady state that requires fewer calories to 
maintain.  This information may help pet owners better understand the need to limit table 
scraps and human-type food snacks in dogs prone to overweight and obesity. 
 In the canine weight loss study, obese dogs were fed diets containing either 
LGI/HGI starch and DAG/TAG for a 10 wk weight loss period.  When the change in 
body weight was considered vs. time among the four diet groups, dogs fed the LGIS 
diets lost a larger percentage of their starting obese body weights than those fed the 
HGIS diets.  The total metabolizable energies of the LGIS diets were considerably lower 
than those of the HGIS diets even though dogs consumed the same amounts of diet on a 
dry weight basis.  Thus, the LGIS dogs had consumed lower amounts of ME overall yet 
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were not denied having a larger volume of food in their daily meal, thereby potentially 
contributing to satiety.  The reason for this difference was primarily because digestibility 
of the LGIS was significantly lower than the HGIS, while differences due to fat types 
were not seen, and protein was only modestly different.  Thus total digestibilities of the 
LGIS diets were less than the HGIS diets overall. 
 In addition to more weight loss, a second benefit of the LGIS diets is that they 
resulted in a significant reduction of circulating insulin when measured over time in 
response to a mixed meal while glucose concentrations were similar in all groups.  Even 
though these effects were independent of dietary oil type, other distinct advantages of 
the DAG oil, when combined with the LGI starch, in a mixed diet were observed.  The 
insulin effect appeared to occur more prominently early on during the weight loss period 
of this study.  By contrast, DAG oil effects appeared to be more pronounced later on in 
the experiment (i.e., wk 8).  Thus, significant post-prandial triacylglycerol lowering was 
observed with the DAG/LGIS compared to the TAG/LGIS combination especially at wk 
8.  Also, post-prandial NEFA concentrations were decreased less with the LGI starch 
containing diets at wk 8.  Taken together, these lipid metabolite changes support the 
possibility of lower triacylglycerol entering the bloodstream after eating (DAG effect) 
while increased relative amounts of NEFA were available for energy in a lower insulin 
environment and while maintaining glucose homeostasis (LGIS effect). 
 Although no diet differences were observed in circulating GIP concentrations at 
wk 1, the positive linear correlation of all diet group data between circulating insulin and 
GIP at 15 and 30 min post-prandially is consistent with the known stimulating effect of 
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GIP on insulin secretion.  Because GIP secretory cells are more abundant in the upper 
part of the small intestine, it follows that there would be an early post-prandial insulin 
stimulatory effect as seen in the present study (i.e., at 15 and 30 min).  When the diets 
were fed for a longer period (i.e., 8 wk), it appeared that the intestinal cells of animals 
fed the HGIS diets continued to secrete amounts of GIP post-prandially further adding to 
a more sustained insulinotropic effect.  Indeed circulating insulin levels were 
significantly higher in the HGIS diets compared with the LGIS diet groups.  It remains 
to be seen whether a longer post-prandial sampling period would further confirm this 
latter possibility. 
 Effects of another insulin secretagogue, GLP-1 was less notable in this study.  No 
effects of diet on GLP-1 were seen yet time effects, post-prandially, were found for this 
polypeptide hormone in the circulation.  It should be noted that the determination of 
circulating levels of GLP-1 does not allow the direct assessment of the actions of GLP-1 
in which numerous interactions among paracrine, endocrine, neural, and luminal 
influences may exist at the cellular level.  In the present study, the sampling schedule 
used (0 to 60 min) may not have been long enough to see any substantial changes in 
GLP-1 although a significant time effect was found during the post-prandial period 
studied.  Obviously numerous other factors including species differences may influence 
the increase of GLP-1 post-prandially in dogs compared with other animals. 
 Plasma adiponectin concentrations observed in the present study were significantly 
higher in the LGIS/DAG diet group compared with all other diet groups.  Higher 
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concentrations of adiponectin compared with the other diets may activate more PPARα 
thus induction of more lipolysis may occur which may also improve insulin resistance. 
 Significantly lower plasma leptin concentrations were observed in all diet 
groups, especially the DAG/LGIS diet group.  Also a positive correlation between leptin 
and body weight was seen.  These findings are similar to those of other investigations, 
and it is concluded that leptin concentration is consistent with weight loss and may thus 
be a reliable marker in dogs as in humans and rodents.   
 In addition to lower digestibility, and an increased, but safe, rate of weight loss, 
these data suggest that the LGIS/DAG diet combination beneficially altered biochemical 
and hormonal parameters such as lower post-prandial TG, lower insulin, GIP, and 
increased adiponectin and decreased plasma leptin concentrations while maintaining 
normal glucose concentrations.  These alterations may help prevent post-prandial 
hyperlipidemia and hyperinsulinemia which are related to obesity and may induce 
obesity related disease such as diabetes mellitus and cardiovascular diseases. 
 Our results demonstrated that the 1,3-DAG diets did not stimulate UCP2 gene 
expression in the canine small intestine during weight reduction.  We observed a more 
prominent starch effect than oil effect.  Although there was no significant difference 
among the diet groups, the combinations of LGI starch and DAG/TAG tended to lower 
UCP2 gene expression in the small intestine compared with the diet combinations of 
HGI starch and DAG/TAG.  From the data obtained, we speculate that the long term 
consumption of a LGIS diet mediates a decrease in UCP2 mRNA expression and is a 
marker of metabolic down regulation associated with lower diet digestibility.  The 
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associated lower metabolizable energy of the LGIS diet resulted in more body weight 
loss compared with the HGIS diets.  Thus, in the face of lowered energy intake from 
LGIS during weight loss, UCP2 may have reduced its uncoupling activity and thereby 
favoring relatively more ATP production than heat generation.  Less expression of UCP2 
in canine small intestine may thus help protect the non-obese state under conditions of 
moderate and/or insufficient energy intake.  It may also may play an adaptive role during 
down regulation of energy metabolism with weight loss.  Although unknown at this time, 
species differences regarding UCP2 expression may also exist.  Finally any potential oil 
effect in canine intestine may be less sensitive or not strong enough to surpass the starch 
or total calorie restriction effects seen on UCP2 gene expression compared with mouse 
intestine where a DAG oil effect was seen. 
 Finally, it should be noted that the diet combination of LGIS/DAG supports 
healthy weight loss and may help prevent obesity related diseases compared with the 
other diet combinations studied.  Although further investigations may be needed, these 
data help characterize the complex nature of obesity and weight management in the 
canine model. 
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APPENDIX A-I 
Diet descriptions 
 
Preconditioning Diet (Obesity induction/re-induction period, 4 weeks; wk -8 to wk -5) 
• Premium quality pet food (Hill’s Science Diet, Adult Original) 
• TAG (50/50 (w/w) mix of commercially available canola and soybean oil) 
• Cookie (Sandies Pecan Shortbread, Keebler, MI) 
 80kcal/cookie (calories from fat: 45 kcal) 
 
Acclimation Diet (Acclimation period, 4 weeks; wk -4 to wk -1) 
• Chicken by-product meal with vitamin/mineral premix 
• Starch (50/50 (w/w) mix of LGI and HGI starch) 
• TAG (50/50 (w/w) mix of commercially available canola and soybean oil) 
 
Treatment Diet (Experimental period, 10 weeks; wk 1 to wk 8) 
LGIS/DAG; LGIS/TAG; HGIS/DAG; HGIS/TAG 
 
Post-prandial Diet (Post-prandial experiment: wk 1 and wk 8) 
• Cooked chicken breast meat (80g) 
• Combinations of LGIS/DAG; LGIS/TAG; HGIS/DAG; HGIS/TAG* 
 *Containing either TAG or DAG (8g) and either LGIS or HGIS (25g) 
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APPENDIX A-II 
Fatty acid composition of acclimation diet* 
Fatty Acid Relative % 
14:0 0.3 
14:1 (n-5) ND 
16:0 13.77 
16:1 (n-7) 2.37 
17:0 ND 
17:1 ND 
18:0 5.11 
18:1 (n-9) 38.15 
18:1 (n-7) 3.17 
18:2 (n-6) 28.31 
18:3 (n-3) 5.45 
20:0 0.56 
20:1 (n-9) 0.62 
20:2 (n-6) ND 
20:3 (n-3) ND 
20:3 (n-6) ND 
20:4 (n-6) 0.41 
20:5 (n-3) ND 
22:0 ND 
22:1 (n-9) ND 
22:4 (n-6) ND 
22:5 (n-3) 0.28 
22:6 (n-3) 0.41 
24:0 0.33 
24:1 (n-9) 0.26 
Unidentified 0.23 
SFA 20.07 
MUFA 44.57 
PUFA 35.13 
n-3 6.14 
n-6 28.99 
 
*19.7% fat (as fed) and 4228 kcal/kg as estimated by calculation from nutrient 
composition using modified Atwater factors.  Values are averages of two representative 
samples.  ND = not detected.; SFA = saturated fatty acids; MUFA = monounsaturated 
fatty acids; PUFA = polyunsaturated fatty acids. 
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APPENDIX A-III 
Description of treatment diet 
Protein source: 
• Low ash chicken by-product meal N/TX 1200 (Tyson Foods, Inc., USA) 
 Protein 70% (Minimum), Fat 12-17% (Target 14.5%) 
 Ash 11% (Maximum), Moisture 3.5-8% (Target 5%) 
Carbohydrate source: 
• Alpha-corn starch and alpha-waxy starch 
  (Nihon Shokuhin Kako Co., Ltd., Tokyo, Japan) 
 1. Low glycemic index (LGI) starch: Alpha-corn starch 
  (70% amylose, 30% amylopectin) 
 2. High glycemic index (HGI) starch: Alpha-waxy starch 
  (100% amylopectin) 
Lipid source: 
• Dietary Diacylglycerol (DAG) and Triacylglycerol (TAG) 
  (Kao Corporation, Tokyo, Japan) 
*Dietary DAG generally contain < 20% of TAG, > 80% of DAG, and < 3% of MAG.  
The ratio of the isoforms of dietary DAG: 1,2-DAG: 30%, 1,3-DAG: 70%) 
*Fat contents is also available from chicken by-product meal. 
Vitamin and Mineral source: 
• Vitamin/Mineral Mix (Premium Adog premix) 
  (North American Nutrition Companies, Inc., Ohio, USA) 
Guaranteed analysis: 
Copper (Cu): 4000 ppm, Iodine (I): 560 ppm, Iron (Fe): 2.40%, Manganese (Mn): 2000 
ppm, Selenium (Se): 120 ppm, Zinc (Zn): 4.32%, Vitamin A: 218 mg/kg (1600000 
IU/lb), Vitamin D3: 2.95 mg/kg (260000 IU/lb), Vitamin E: 5455 (5443) mg/kg (12000 
IU/lb), Vitamin B12: 1.82 mg/kg (4 mg/lb), Riboflavin: 272.7 mg/kg (600 mg/lb), d-
Pantothenic acid: 1364 mg/kg (3000 mg/lb), Thiamine: 75 mg/kg (165 mg/lb), Niacin: 
3182 mg/kg (7000 mg/lb), Vitamin B6: 90.9 mg/kg (200 mg/lb), Folic acid: 143.6 mg/kg 
(316 mg/lb), Choline chloride: 41227 mg/kg (90700 mg/lb), Choline: 35811 mg/kg 
(78784 mg/lb), d-Biotin: 4.5 mg/kg (10 mg/lb). *ppm = µg/g (mg/kg), vitamin A: 1 IU = 
0.3 µg, vitamin D3: 40 IU = 1 µg, vitamin E: 1 IU = 1 mg. 
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APPENDIX A-IV 
Fatty acid composition of oil containing food components (relative %) 
 
 Fatty Acid TAG DAG Chicken 
14:0 0.07 0.03 0.46 
16:0 4.94 2.76 28.64 
16:1(n-7) 0.14 0.11 4.35 
17:0 0.09 0.09 0.12 
18:0 1.89 1.33 12.48 
18:1 (n-9) 32.09 37.34 27.07 
18:1 (n-7) 1.79 2.17 6.01 
18:2 (n-6) 50.31 47.6 11.73 
18:3 (n-3) 7.49 6.57 0.38 
20:0 0.36 0.33 0.1 
20:1 (n-9) 0.63 0.7 0.33 
20:2 (n-6) 0.06 0.07 0.3 
20:3 (n-6) ND ND 0.62 
20:4 (n-6) ND ND 2.49 
22:0 0.26 0.29 ND 
22:1 0.14 0.05 ND 
24:0/22:6 (n-3) 0.09 0.1 0.4 
24:1 (n-9) 0.1 0.1 0.32 
Unidentified 1.34 2.53 4.22 
 
 
Values are average of two representative samples (g/100 g total fatty acid). 
ND = not detected. 
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APPENDIX A-V 
Fatty acid composition of treatment diets* (relative %) 
 Diet 
Fatty Acid LGIS/DAG LGIS/TAG HGIS/DAG HGIS/TAG 
14:0 0.23 0.19 0.25 0.38 
14:1 (n-5) ND ND TR ND 
16:0 11.55 12.54 10.3 16.4 
16:1 (n-7) 2.15 1.89 2.26 3.52 
17:0 TR 0.1 TR 0.12 
17:1 0.11 ND 0.11 ND 
18:0 4.11 5.36 3.89 5.66 
18:1 (n-9) 39.67 37.55 38.74 36.57 
18:1 (n-7) 3.89 1.68 2.89 3.31 
18:2 (n-6) 30.1 29.86 32.91 27.08 
18:3 (n-3) 2.76 3.28 3.33 2.93 
20:0 0.41 0.65 0.72 0.42 
20:1 (n-9) 0.93 0.94 0.65 0.58 
20:2 (n-6) ND 0.17 ND ND 
20:3 (n-3) ND ND ND ND 
20:3 (n-6) ND ND ND ND 
20:4 (n-6) 0.37 0.28 0.43 0.37 
20:5 (n-3) ND ND ND ND 
22:0 TR 0.6 0.39 0.41 
22:1 (n-9) ND 0.19 TR 0.13 
22:4 (n-6) TR ND TR ND 
22:5 (n-3) ND ND ND ND 
22:6 (n-3) 0.36 0.78 0.42 0.68 
24:0 ND ND ND ND 
24:1 (n-9) 0.6 0.55 0.49 0.63 
Unidentified 2.53 1.38 1.92 1.2 
SFA 16.46 19.44 15.64 23.39 
MUFA 47.35 44.8 45.27 44.74 
PUFA 33.67 34.37 37.18 31.05 
n-3 3.12 4.06 3.75 3.6 
n-6 30.55 30.31 33.43 27.45 
*All diets 19.7% fat (as fed) and 4228 kcal/kg as estimated by calculation from nutrient 
composition using modified Atwater factors.  Values are averages of two representative 
samples.  ND = not detected; TR = trace (< 0.1%); SFA = saturated fatty acids; MUFA = 
monounsaturated fatty acids; PUFA = polyunsaturated fatty acids. 
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